CA2897955C - Extract from culture medium of ceriporia lacerata for prevention or treatment of diabetic diseases and complications - Google Patents
Extract from culture medium of ceriporia lacerata for prevention or treatment of diabetic diseases and complications Download PDFInfo
- Publication number
- CA2897955C CA2897955C CA2897955A CA2897955A CA2897955C CA 2897955 C CA2897955 C CA 2897955C CA 2897955 A CA2897955 A CA 2897955A CA 2897955 A CA2897955 A CA 2897955A CA 2897955 C CA2897955 C CA 2897955C
- Authority
- CA
- Canada
- Prior art keywords
- extract
- exopolysaccharide
- culture
- diabetic
- ceriporia lacerata
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001466515 Emmia lacerata Species 0.000 title claims abstract description 87
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 49
- 239000001963 growth medium Substances 0.000 title claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 24
- 230000002265 prevention Effects 0.000 title claims description 8
- 239000000284 extract Substances 0.000 title abstract description 64
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract description 25
- 206010012655 Diabetic complications Diseases 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 229920002444 Exopolysaccharide Polymers 0.000 claims description 114
- 235000000346 sugar Nutrition 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 201000001421 hyperglycemia Diseases 0.000 claims description 4
- 206010062198 microangiopathy Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 108
- 239000008103 glucose Substances 0.000 description 67
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 61
- 102000004877 Insulin Human genes 0.000 description 54
- 108090001061 Insulin Proteins 0.000 description 54
- 229940125396 insulin Drugs 0.000 description 54
- 210000004369 blood Anatomy 0.000 description 48
- 239000008280 blood Substances 0.000 description 48
- 239000000243 solution Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 30
- 239000000843 powder Substances 0.000 description 30
- 230000000694 effects Effects 0.000 description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- 235000013312 flour Nutrition 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 210000001789 adipocyte Anatomy 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 230000004190 glucose uptake Effects 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 238000012258 culturing Methods 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 11
- 235000019796 monopotassium phosphate Nutrition 0.000 description 11
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 10
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108091007960 PI3Ks Proteins 0.000 description 9
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 9
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 239000011785 micronutrient Substances 0.000 description 9
- 235000013369 micronutrients Nutrition 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 8
- 108091006300 SLC2A4 Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 8
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 8
- 235000019797 dipotassium phosphate Nutrition 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000009630 liquid culture Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000007836 KH2PO4 Substances 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 239000004382 Amylase Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 5
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 5
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 description 5
- 102000016267 Leptin Human genes 0.000 description 5
- 108010092277 Leptin Proteins 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 240000006394 Sorghum bicolor Species 0.000 description 5
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 238000005227 gel permeation chromatography Methods 0.000 description 5
- 229940039781 leptin Drugs 0.000 description 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 5
- 235000019624 protein content Nutrition 0.000 description 5
- 229960003371 protocatechualdehyde Drugs 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 231100000820 toxicity test Toxicity 0.000 description 5
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010075254 C-Peptide Proteins 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- 102000003746 Insulin Receptor Human genes 0.000 description 4
- 108010001127 Insulin Receptor Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 4
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 210000000579 abdominal fat Anatomy 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000010030 glucose lowering effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000123410 Ceriporia Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000037041 intracellular level Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 239000012137 tryptone Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108700022174 Drosophila Son of Sevenless Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000010200 folin Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 150000002303 glucose derivatives Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 108010019813 leptin receptors Proteins 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000013028 medium composition Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 150000003906 phosphoinositides Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000003752 saphenous vein Anatomy 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 239000011686 zinc sulphate Substances 0.000 description 2
- 235000009529 zinc sulphate Nutrition 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 108010012196 90-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000019050 90-kDa Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000031638 Body Weight Diseases 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 1
- 101710201820 Insulin receptor substrate 2 Proteins 0.000 description 1
- 102100031419 Insulin receptor substrate 4 Human genes 0.000 description 1
- 101710201816 Insulin receptor substrate 4 Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 101150046735 LEPR gene Proteins 0.000 description 1
- 101150063827 LEPROT gene Proteins 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 102100031775 Leptin receptor Human genes 0.000 description 1
- 101001063890 Mus musculus Leptin Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 241001480065 Quercus serrata Species 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- -1 glucose transfer Chemical compound 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011664 type 2 diabetes animal model Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
The present invention relates to a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata and a pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications prepared by the preparation method. According to the method for preparing an extract from the mycelial culture medium of Ceriporia lacerata, the extract contains a relatively high content of expolysaccharides in comparison with the conventional preparation method according to a prior document by these inventors and thus will be capable of being used as an ingredient for a pharmaceutical composition for diabetic diseases or a relevant functional food.
Description
OR TREATMENT OF DIABETIC DISEASES AND COMPLICATIONS
FIELD OF THE INVENTION
The present invention relates to a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata and a pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications prepared by the preparation method.
DESCRIPTION OF THE PRIOR ART
Ceriporia lacerate is a kind of white-rotting fungus and performs co-metabolism, i.e.,lignin decomposition, in order to use carbon sources such as cellulose, hemi-cellulose, etc. in the ecosystem.
The presence of Ceriporia lacerata was reported first in 2002, and for this reason, there have been very few studies on the industrialization of Ceriporia lacerata.
Only two 20 types of studies on the use of Ceriporia lacerata for preventing soil contamination and bleaching have been reported.
With respect to studies on the use of Ceriporia lacerate for foods and drugs, Korean Patent No. 10-1031605 entitled "method for preparing Ceriporia lorPrata culture extract for prevention and treatment of diabetic disease and Ceriporia lacerata culture extract prepared thereby," which was filed in the name of the present inventors, is the only study in the world.
However, the above patent document mentions only the effect of the extract against Type 1 diabetes.
Diabetes therapeutic agents developed to date include blood glucose-lowering agents and insulin injections, but these agents merely delay the progression of diabetes and do not function as agents for preventing and treating diabetes.
For the treatment of diabetes and diabetic complications, a substance for arresting the progression of the diseases is required to be developed. In addition, a substance for either regenerating pancreatic beta-cells that regulate insulin secretion or promoting the regeneration of pancreatic beta-cells is required to be developed.
The present inventors have discovered that the marker substance, exopolysaccharide, contained in a Ceriporia lacerata mycelium culture and a dried substance thereof is a very effective substance for blocking the progression of diabetes and promoting the regeneration of pancreatic beta-cells. Thus, there is an urgent need for studies on the identification of the structure of exopolysaccharide in Ceriporia lacerata and the discovery of an optimal culture method for increasing the content of the exopolysaccharide.
DETAILED DESCRIPTION OF THE INVENTION
PROBLEMS TO BE SOLVED BY THE INVENTION
Accordingly, the present invention has been made in order to solve the above-described problems occurring in the prior art, and it is an object of the present invention to provide an improved method for preparing an extract from the mycelial culture medium of Ceriporia lacerata, which can increase the content of exopolysaccharide.
Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications, which contains, as an active ingredient, an extract from the mycelial culture medium of Ceriporia lacerata having an increased content of exopolysaccharide prepared by the preparation method.
MEANS TO SOLVE THE PROBLEMS
FIELD OF THE INVENTION
The present invention relates to a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata and a pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications prepared by the preparation method.
DESCRIPTION OF THE PRIOR ART
Ceriporia lacerate is a kind of white-rotting fungus and performs co-metabolism, i.e.,lignin decomposition, in order to use carbon sources such as cellulose, hemi-cellulose, etc. in the ecosystem.
The presence of Ceriporia lacerata was reported first in 2002, and for this reason, there have been very few studies on the industrialization of Ceriporia lacerata.
Only two 20 types of studies on the use of Ceriporia lacerata for preventing soil contamination and bleaching have been reported.
With respect to studies on the use of Ceriporia lacerate for foods and drugs, Korean Patent No. 10-1031605 entitled "method for preparing Ceriporia lorPrata culture extract for prevention and treatment of diabetic disease and Ceriporia lacerata culture extract prepared thereby," which was filed in the name of the present inventors, is the only study in the world.
However, the above patent document mentions only the effect of the extract against Type 1 diabetes.
Diabetes therapeutic agents developed to date include blood glucose-lowering agents and insulin injections, but these agents merely delay the progression of diabetes and do not function as agents for preventing and treating diabetes.
For the treatment of diabetes and diabetic complications, a substance for arresting the progression of the diseases is required to be developed. In addition, a substance for either regenerating pancreatic beta-cells that regulate insulin secretion or promoting the regeneration of pancreatic beta-cells is required to be developed.
The present inventors have discovered that the marker substance, exopolysaccharide, contained in a Ceriporia lacerata mycelium culture and a dried substance thereof is a very effective substance for blocking the progression of diabetes and promoting the regeneration of pancreatic beta-cells. Thus, there is an urgent need for studies on the identification of the structure of exopolysaccharide in Ceriporia lacerata and the discovery of an optimal culture method for increasing the content of the exopolysaccharide.
DETAILED DESCRIPTION OF THE INVENTION
PROBLEMS TO BE SOLVED BY THE INVENTION
Accordingly, the present invention has been made in order to solve the above-described problems occurring in the prior art, and it is an object of the present invention to provide an improved method for preparing an extract from the mycelial culture medium of Ceriporia lacerata, which can increase the content of exopolysaccharide.
Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications, which contains, as an active ingredient, an extract from the mycelial culture medium of Ceriporia lacerata having an increased content of exopolysaccharide prepared by the preparation method.
MEANS TO SOLVE THE PROBLEMS
2 To achieve the above objects, the present disclosure provides a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata, which comprises the steps of culturing the mycelia of Ceriporia lacerata in a liquid, drying the culture to form powder and-preparing a solvent extract from the powder, wherein a medium for culturing the mycelia of Ceriporia lacerata comprises 1-2 wt% of sugar, 0.2-1 wt% of glucose, 0.2-1 wt% of starch, 0.1-0.5 wt% of sorghum powder, 0.1-0.5 wt% of barley powder, 0.2-2 wt% of soy flour, 0.05-0.1 wt% of magnesium sulfate (MgSO4), 0.05-0.1 wt% of monopotassium phosphate (KH2PO4), 0.05-0.1 wt% of dipotassium phosphate (1C2,1-1PO4) and 92-98 wt% of water and has a pH of 4.5-6Ø
The culturing is preferably carried out under a blue LED light source.
The culturing is preferably carried out at a carbon dioxide concentration of 1,0002,000 ppm.
The present disclosure also provides a pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications, which contains, as an active ingredient 15 an extract from the mycelial culture medium of Ceriporia lacerata having an increased content of exopolysaccharide prepared by the preparation method.
In one aspect, the present invention provides a purified exopolysaccharide (EPS) having a molecular weight of about 120 kDa for use in the prevention or treatment of a diabetic disease or a diabetic complication, wherein said exopolysaccharide is obtained from a culture medium of Ceriporia lacerate mycelia.
In another aspect, the present invention provides use of a purified exopolysaccharide (EPS) having a molecular weight of about 120 kDa for the prevention or treatment of a diabetic disease or a diabetic complication, wherein said exopolysaccharide is obtained from a culture medium of Ceriporia lacerate mycelia.
In another aspect, the present invention provides use of a purified exopolysaccharide (EPS) having a molecular weight of about 120 kDa in the preparation of a medicament for the prevention or treatment of a diabetic disease or a diabetic complication, wherein said exopolysaccharide is obtained from a culture medium of Ceriporia lacerate mycelia.
The culturing is preferably carried out under a blue LED light source.
The culturing is preferably carried out at a carbon dioxide concentration of 1,0002,000 ppm.
The present disclosure also provides a pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications, which contains, as an active ingredient 15 an extract from the mycelial culture medium of Ceriporia lacerata having an increased content of exopolysaccharide prepared by the preparation method.
In one aspect, the present invention provides a purified exopolysaccharide (EPS) having a molecular weight of about 120 kDa for use in the prevention or treatment of a diabetic disease or a diabetic complication, wherein said exopolysaccharide is obtained from a culture medium of Ceriporia lacerate mycelia.
In another aspect, the present invention provides use of a purified exopolysaccharide (EPS) having a molecular weight of about 120 kDa for the prevention or treatment of a diabetic disease or a diabetic complication, wherein said exopolysaccharide is obtained from a culture medium of Ceriporia lacerate mycelia.
In another aspect, the present invention provides use of a purified exopolysaccharide (EPS) having a molecular weight of about 120 kDa in the preparation of a medicament for the prevention or treatment of a diabetic disease or a diabetic complication, wherein said exopolysaccharide is obtained from a culture medium of Ceriporia lacerate mycelia.
3 The diabetic diseases may be Type 2 diabetes.
The diabetic complications may be selected from the group consisting of hyperglycemia, atherosclerosis, microangiopathy, diabetic retinopathy and kidney disease.
EFFECTS OF THE INVENTION
According to the method for preparing an extract from the mycelial culture medium of Ceriporia lacerate, the extract prepared according to the inventive method has a relatively high content of exopolysaccharides in comparison with the extract prepared by the method described in the prior art document of the present inventors, and thus it can be used as an active ingredient for a pharmaceutical composition for diabetic diseases or a relevant functional food.
3a t.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGs. la and lb show the results of ITS-5.8S rDNA sequencing of a Ceriporia lacerata strain according to the present invention.
FIG. 2a is a graph showing the content of residual sugar depending on pH and the kind of sugar in the culture of a Ceriporia lacerata strain, and FIG. 2b is a photograph showing culture products.
FIG. 3 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on the kind of sugar.
FIG. 4 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on the concentration of glucose.
FIG. 5 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on a nitrogen source.
FIG. 6 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on the concentration of soy flour as a nitrogen source.
FIG. 7 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on trace elements.
FIG. 8 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on the concentration of the trace element MgSO4.
FIG. 9 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on culture time in a 5L culture medium.
FIG. 10 is a graph showing the results of measuring the molecular weight of exopolysaccharide in a purified culture.
FIG. 11 schematically shows an experimental process for analyzing the activity of an extract from the mycelial culture medium of Ceriporia lacerata of the present invention against diabetes.
FIG. 12 shows the food intake of Type 2 diabetic mice treated with a Ceriporia
The diabetic complications may be selected from the group consisting of hyperglycemia, atherosclerosis, microangiopathy, diabetic retinopathy and kidney disease.
EFFECTS OF THE INVENTION
According to the method for preparing an extract from the mycelial culture medium of Ceriporia lacerate, the extract prepared according to the inventive method has a relatively high content of exopolysaccharides in comparison with the extract prepared by the method described in the prior art document of the present inventors, and thus it can be used as an active ingredient for a pharmaceutical composition for diabetic diseases or a relevant functional food.
3a t.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGs. la and lb show the results of ITS-5.8S rDNA sequencing of a Ceriporia lacerata strain according to the present invention.
FIG. 2a is a graph showing the content of residual sugar depending on pH and the kind of sugar in the culture of a Ceriporia lacerata strain, and FIG. 2b is a photograph showing culture products.
FIG. 3 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on the kind of sugar.
FIG. 4 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on the concentration of glucose.
FIG. 5 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on a nitrogen source.
FIG. 6 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on the concentration of soy flour as a nitrogen source.
FIG. 7 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on trace elements.
FIG. 8 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on the concentration of the trace element MgSO4.
FIG. 9 is a graph showing the growth of mycelia and the content of exopolysaccharide depending on culture time in a 5L culture medium.
FIG. 10 is a graph showing the results of measuring the molecular weight of exopolysaccharide in a purified culture.
FIG. 11 schematically shows an experimental process for analyzing the activity of an extract from the mycelial culture medium of Ceriporia lacerata of the present invention against diabetes.
FIG. 12 shows the food intake of Type 2 diabetic mice treated with a Ceriporia
4 lacerata mycelium culture extract.
FIG. 13 shows the water intake of Type 2 diabetic mice treated with a Ceriporia lacerata mycelium culture extract.
FIG. 14 shows the pattern of bodyweig,ht increase in Type 2 diabetic mice treated with a Ceriporia lacerata mycelium culture extract.
FIG. 15 shows liver conditions of a normal mouse Type 2 diabetic mice and a mouse treated with a Ceriporia lacerata mycelium culture extract.
FIG. 16 is a graph showing blood glucose levels depending on time.
FIG. 17 is a graph showing blood glucose levels depending on time after oral administration of glucose.
FIG. 18 is a graph showing blood glucose levels after sacrifice of mice fed with a Ceriporia lacerata mycelium culture extract for 6 weeks.
FIGs. 19a and 19b are a graph and a micrograph, which show that a Ceriporia lacerata mycelium culture extract promotes adipocyte differentiation in a manner similar to insulin.
FIG. 20 is a graph showing the degree of adipocyte differentiation by a Ceriporia lacerata mycelium culture extract depending on the presence or absence of insulin.
FIGs. 21a and 21b show insulin signaling in adipocytes by a Ceriporia lacerata mycelium culture extract.
FIG. 22 is a graph showing the expression level of GLUT4 in adipocytes by a Ceriporia lacerata mycelium culture extract.
BEST MODE FOR CARRYING OUT THE INVENTION
In the present invention, there is provided a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata, which comprises the steps of: culturing the mycelia of Ceriporia lacerata in a liquid, drying the culture to form powder and preparing a solvent extract from the powder, wherein a medium for culturing the mycelia of Ceriporia lacerata comprises 1-2 wt% of sugar, 0.2-1 wt% of glucose, 0.2-1 wt%
of starch,
FIG. 13 shows the water intake of Type 2 diabetic mice treated with a Ceriporia lacerata mycelium culture extract.
FIG. 14 shows the pattern of bodyweig,ht increase in Type 2 diabetic mice treated with a Ceriporia lacerata mycelium culture extract.
FIG. 15 shows liver conditions of a normal mouse Type 2 diabetic mice and a mouse treated with a Ceriporia lacerata mycelium culture extract.
FIG. 16 is a graph showing blood glucose levels depending on time.
FIG. 17 is a graph showing blood glucose levels depending on time after oral administration of glucose.
FIG. 18 is a graph showing blood glucose levels after sacrifice of mice fed with a Ceriporia lacerata mycelium culture extract for 6 weeks.
FIGs. 19a and 19b are a graph and a micrograph, which show that a Ceriporia lacerata mycelium culture extract promotes adipocyte differentiation in a manner similar to insulin.
FIG. 20 is a graph showing the degree of adipocyte differentiation by a Ceriporia lacerata mycelium culture extract depending on the presence or absence of insulin.
FIGs. 21a and 21b show insulin signaling in adipocytes by a Ceriporia lacerata mycelium culture extract.
FIG. 22 is a graph showing the expression level of GLUT4 in adipocytes by a Ceriporia lacerata mycelium culture extract.
BEST MODE FOR CARRYING OUT THE INVENTION
In the present invention, there is provided a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata, which comprises the steps of: culturing the mycelia of Ceriporia lacerata in a liquid, drying the culture to form powder and preparing a solvent extract from the powder, wherein a medium for culturing the mycelia of Ceriporia lacerata comprises 1-2 wt% of sugar, 0.2-1 wt% of glucose, 0.2-1 wt%
of starch,
5 0.1-0.5 wt% of sorghum powder, 0.1-0.5 wt% of barley powder, 0.2-2 wt% of soy flour, 0.05-0.1 wt% of magnesium sulfate (MgSO4), 0.05-0.1 wt% of monopotassium phosphate (KH2PO4), 0.05-0.1 wt% of dipotassium phosphate (K2HPO4) and 92-98 wt% of water and has a pH of 4.5-6Ø
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail.
The present inventors have found that a marker substance having excellent effects of blocking the progression of diabetes and diabetic complications and promoting the regeneration of beta-cells is the exopolysaccharide of a Ceriporia lacerata mycelium culture extract, and the present inventors have developed a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata, which can increase the content of the exopolysaccharide, and a pharmaceutical composition for preventing or treating diabetes and diabetic complications, which contains the extract from the mycelial culture medium of Ceriporia lacerata, thereby completing the present invention.
Therefore, the present invention provides a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata, which comprises the steps of:
culturing the mycelia of Ceriporia lacerata in a liquid, drying the culture to form powder and preparing a solvent extract from the powder, wherein a medium for culturing the mycelia of Ceriporia lacerata comprises 1-2 wt% of sugar, 0.2-1 wt% of glucose, 0.2-1 wt% of starch, 0.1-0.5 wt%
of sorghum powder, 0.1-0.5 wt% of barley powder, 0.2-2 wt% of soy flour, 0.05-0.1 wt% of magnesium sulfate (MgSO4), 0.05-0.1 wt% of monopotassium phosphate (KH2PO4), 0.05-0.1 wt% of dipotassium phosphate (K2HPO4) and 92-98 wt% of water and has a pH
of 4.5-6Ø
The culturing is preferably carried out under a blue LED light source.
The culturing is preferably carried out at a carbon dioxide concentration of 1,000-2,000 ppm.
DETAILED DESCRIPTION OF THE INVENTION
Hereinafter, the present invention will be described in detail.
The present inventors have found that a marker substance having excellent effects of blocking the progression of diabetes and diabetic complications and promoting the regeneration of beta-cells is the exopolysaccharide of a Ceriporia lacerata mycelium culture extract, and the present inventors have developed a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata, which can increase the content of the exopolysaccharide, and a pharmaceutical composition for preventing or treating diabetes and diabetic complications, which contains the extract from the mycelial culture medium of Ceriporia lacerata, thereby completing the present invention.
Therefore, the present invention provides a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata, which comprises the steps of:
culturing the mycelia of Ceriporia lacerata in a liquid, drying the culture to form powder and preparing a solvent extract from the powder, wherein a medium for culturing the mycelia of Ceriporia lacerata comprises 1-2 wt% of sugar, 0.2-1 wt% of glucose, 0.2-1 wt% of starch, 0.1-0.5 wt%
of sorghum powder, 0.1-0.5 wt% of barley powder, 0.2-2 wt% of soy flour, 0.05-0.1 wt% of magnesium sulfate (MgSO4), 0.05-0.1 wt% of monopotassium phosphate (KH2PO4), 0.05-0.1 wt% of dipotassium phosphate (K2HPO4) and 92-98 wt% of water and has a pH
of 4.5-6Ø
The culturing is preferably carried out under a blue LED light source.
The culturing is preferably carried out at a carbon dioxide concentration of 1,000-2,000 ppm.
6 , In a preferred embodiment of the present invention, the extract from the mycelial culture medium of Ceriporia lacerata can be prepared by a method comprising the following steps:
(a) culturing the mycelia of Ceriporia lacerata to obtain a mycelia culture of Ceriporia lacerata;
(b) vacuum-drying or freeze-drying the culture to form powder; and (c) subjecting the powder to extraction with one or more solvents selected from the group consisting of water, ethanol and methanol.
The liquid culture of Ceriporia lacerata mycelia in step (a) is performed by culturing the mycelia of Ceriporia lacerata in a liquid to obtain exopolysaccharide. A
medium composition for the liquid culture may comprise 1-2 wt% of sugar, 0.2-1 wt% of glucose, 0.2-1 wt% of starch, 0.1-0.5 wt% of sorghum powder, 0.1-0.5 wt% of barley powder, 0.2-2 wt% of soy flour, 0.05-0.1 wt% of magnesium sulfate (MgSO4), 0.05-0.1 wt% of monopotassium phosphate (KH2PO4), 0.05-0.1 wt% of dipotassium phosphate (K2HPO4) and 92-98 wt% of water.
Herein, the liquid culture is preferably performed at a temperature of 20 to 25 C, a pH of 4.5-6.0, an illumination intensity of 0.5 LUX, an air injection rate of 0.5-1.5 kgf/cm2 and a carbon dioxide concentration of 1,000-2,000 ppm for 8-13 days using a blue LED light source. Most preferably, the liquid culture is performed under the conditions of 22 C, pH 5, an air injection rate of 1.0 kgFcm2 and a carbon dioxide concentration of 1,500 ppm for 10 days to make the content of exopolysaccharide high.
The parent strain that is used in step (a) is a strain obtained by culturing an excellent strain, stored in PDA medium at 4 C, in a shaking incubator at 25 C for 7-9 days using PDB
medium in an Erlenmeyer flask. Herein, the amount of the mycelium to be inoculated is most preferably 0.5% of the solution to be incubated. Because an increase in the mycelium amount (%/100 mL) does not lead to an increase in the content of exopolysaccharide, the medium composition should have selective culture conditions which are not based on the best
(a) culturing the mycelia of Ceriporia lacerata to obtain a mycelia culture of Ceriporia lacerata;
(b) vacuum-drying or freeze-drying the culture to form powder; and (c) subjecting the powder to extraction with one or more solvents selected from the group consisting of water, ethanol and methanol.
The liquid culture of Ceriporia lacerata mycelia in step (a) is performed by culturing the mycelia of Ceriporia lacerata in a liquid to obtain exopolysaccharide. A
medium composition for the liquid culture may comprise 1-2 wt% of sugar, 0.2-1 wt% of glucose, 0.2-1 wt% of starch, 0.1-0.5 wt% of sorghum powder, 0.1-0.5 wt% of barley powder, 0.2-2 wt% of soy flour, 0.05-0.1 wt% of magnesium sulfate (MgSO4), 0.05-0.1 wt% of monopotassium phosphate (KH2PO4), 0.05-0.1 wt% of dipotassium phosphate (K2HPO4) and 92-98 wt% of water.
Herein, the liquid culture is preferably performed at a temperature of 20 to 25 C, a pH of 4.5-6.0, an illumination intensity of 0.5 LUX, an air injection rate of 0.5-1.5 kgf/cm2 and a carbon dioxide concentration of 1,000-2,000 ppm for 8-13 days using a blue LED light source. Most preferably, the liquid culture is performed under the conditions of 22 C, pH 5, an air injection rate of 1.0 kgFcm2 and a carbon dioxide concentration of 1,500 ppm for 10 days to make the content of exopolysaccharide high.
The parent strain that is used in step (a) is a strain obtained by culturing an excellent strain, stored in PDA medium at 4 C, in a shaking incubator at 25 C for 7-9 days using PDB
medium in an Erlenmeyer flask. Herein, the amount of the mycelium to be inoculated is most preferably 0.5% of the solution to be incubated. Because an increase in the mycelium amount (%/100 mL) does not lead to an increase in the content of exopolysaccharide, the medium composition should have selective culture conditions which are not based on the best
7 =
nutrient ratio and environmental conditions for the growth of mycelia, but the conditions for maximizing the content of exopolysaccharide.
The culture solution is separated into mycelia and an aqueous solution. The separation is performed by removing mycelia from the culture solution using a centrifuge and repeatedly purifying the remaining solution using a multi-sheet filter press and a vibrating membrane separator (PALLSEP), followed by irradiation with UV rays for I
minute. Also, the culture solution should be sealed and stored after the removal of oxygen.
This is because the presence of mycelia in the culture solution results in the change in the content of the active ingredient due to the growth of the mycelia.
In step (b), the mycelium culture solution prepared in step (a) is vacuum-dried or freeze-dried to form powder. When the drying is carried out at high temperature, a significant portion of the active ingredient can be lost. For this reason, the drying is carried out at a temperature of 40 C or lower, preferably 30 C or lower, for 48-96 hours. In addition, for the drying in step (b), a vacuum freeze dryer is preferably used compared to a vacuum dryer in which a relatively high evaporation temperature is set, in order to minimize the change in the content of the active substance.
In step (c), the dried mycelial culture obtained in step (b) is subjected to extraction with a solvent, thereby preparing an extract from the mycelial culture medium of Ceriporia lacerata containing exopolysaccharide according to the present invention.
In step (c), 5 g of the dried powder is sufficiently suspended in 100 mL of distilled water, and the suspension is centrifuged at 8,000 rpm for 20 minutes. A 2-3-fold amount of cold alcohol is added to the supematant, and the solution was placed in a refrigerator at 4 C
and allowed to stand for 12 hours.
The supernatant in the solution which had been allowed to stand is centrifuged again at 8,000 rpm for 20 minutes, and the precipitate is recovered, thereby preparing crude exopolysaccharide. The extract is preferably vacuum-freeze-dried at 30 C or lower.
The extract from the mycelial culture medium of Ceriporia lacerata prepared according to the present invention as described above has significantly high contents of active
nutrient ratio and environmental conditions for the growth of mycelia, but the conditions for maximizing the content of exopolysaccharide.
The culture solution is separated into mycelia and an aqueous solution. The separation is performed by removing mycelia from the culture solution using a centrifuge and repeatedly purifying the remaining solution using a multi-sheet filter press and a vibrating membrane separator (PALLSEP), followed by irradiation with UV rays for I
minute. Also, the culture solution should be sealed and stored after the removal of oxygen.
This is because the presence of mycelia in the culture solution results in the change in the content of the active ingredient due to the growth of the mycelia.
In step (b), the mycelium culture solution prepared in step (a) is vacuum-dried or freeze-dried to form powder. When the drying is carried out at high temperature, a significant portion of the active ingredient can be lost. For this reason, the drying is carried out at a temperature of 40 C or lower, preferably 30 C or lower, for 48-96 hours. In addition, for the drying in step (b), a vacuum freeze dryer is preferably used compared to a vacuum dryer in which a relatively high evaporation temperature is set, in order to minimize the change in the content of the active substance.
In step (c), the dried mycelial culture obtained in step (b) is subjected to extraction with a solvent, thereby preparing an extract from the mycelial culture medium of Ceriporia lacerata containing exopolysaccharide according to the present invention.
In step (c), 5 g of the dried powder is sufficiently suspended in 100 mL of distilled water, and the suspension is centrifuged at 8,000 rpm for 20 minutes. A 2-3-fold amount of cold alcohol is added to the supematant, and the solution was placed in a refrigerator at 4 C
and allowed to stand for 12 hours.
The supernatant in the solution which had been allowed to stand is centrifuged again at 8,000 rpm for 20 minutes, and the precipitate is recovered, thereby preparing crude exopolysaccharide. The extract is preferably vacuum-freeze-dried at 30 C or lower.
The extract from the mycelial culture medium of Ceriporia lacerata prepared according to the present invention as described above has significantly high contents of active
8 =
=
ingredients effective for the treatment of steroid-induced diabetes, and thus has an excellent effect of arresting and treating diabetes-related diseases and complications.
More specifically, the extract from the mycelial culture medium of Ceriporia lacerata according to the present invention contains exopolysaccharide having anti-diabetic effects in an amount of 0.3 0.03%/1L. In addition, the dried extract contains the exopolysaccharide in an amount of 5.00 0.02%/100 g.
The present invention also provides a pharmaceutical composition for preventing or treating diabetes and diabetic complications, which contains, as an active ingredient, an extract from the mycelial culture medium of Geri poria lacerata prepared by the above method.
The diabetic diseases may be Type 2 diabetes.
The diabetic complications may be selected from the group consisting of hyperglycemia, atherosclerosis, microangiopathy, diabetic retinopathy and kidney disease.
The pharmaceutical composition which contains, as an active ingredient, the extract from the mycelial culture medium of Ceriporia lacerata prepared by the above method, may further contain a suitable carrier, excipient or diluent known in the art.
For example, a powder formulation may be prepared by mixing 200 mg of the extract, 100 mg of rice powder and 10 mg of talc and packing the mixture into an airtight bag.
For example, a tablet formulation is prepared by mixing 100 mg of the extract, mg of rice powder, 10 mg of lactose and 2 mg of magnesium stearate and compressing the mixture into a tablet.
For example, a liquid formulation is prepared by mixing 100 mL of the extract, 5 g of isomerized sugar, a suitable amount of pine fragrance and a suitable amount of a preservative and packing the mixture in a brown bottle. In this case, the resultant material of step (a) may be used directly instead of the extract.
Hereinafter, the present invention will be described in further detail with reference to examples. It is to be understood, however, that these examples are for illustrative purposes and are not intended to limit the scope of the present invention.
=
ingredients effective for the treatment of steroid-induced diabetes, and thus has an excellent effect of arresting and treating diabetes-related diseases and complications.
More specifically, the extract from the mycelial culture medium of Ceriporia lacerata according to the present invention contains exopolysaccharide having anti-diabetic effects in an amount of 0.3 0.03%/1L. In addition, the dried extract contains the exopolysaccharide in an amount of 5.00 0.02%/100 g.
The present invention also provides a pharmaceutical composition for preventing or treating diabetes and diabetic complications, which contains, as an active ingredient, an extract from the mycelial culture medium of Geri poria lacerata prepared by the above method.
The diabetic diseases may be Type 2 diabetes.
The diabetic complications may be selected from the group consisting of hyperglycemia, atherosclerosis, microangiopathy, diabetic retinopathy and kidney disease.
The pharmaceutical composition which contains, as an active ingredient, the extract from the mycelial culture medium of Ceriporia lacerata prepared by the above method, may further contain a suitable carrier, excipient or diluent known in the art.
For example, a powder formulation may be prepared by mixing 200 mg of the extract, 100 mg of rice powder and 10 mg of talc and packing the mixture into an airtight bag.
For example, a tablet formulation is prepared by mixing 100 mg of the extract, mg of rice powder, 10 mg of lactose and 2 mg of magnesium stearate and compressing the mixture into a tablet.
For example, a liquid formulation is prepared by mixing 100 mL of the extract, 5 g of isomerized sugar, a suitable amount of pine fragrance and a suitable amount of a preservative and packing the mixture in a brown bottle. In this case, the resultant material of step (a) may be used directly instead of the extract.
Hereinafter, the present invention will be described in further detail with reference to examples. It is to be understood, however, that these examples are for illustrative purposes and are not intended to limit the scope of the present invention.
9 . , Examples 1. Preparation of Ceriporia lacerata culture extract 1-1. Preparation of Ceriporia lacerata culture Ceriporia lacerata was isolated from Quercus serrata and subcultured to obtain a parent strain which was then freeze-stored at -80 C. The stored strain was subcultured 2-3 times in PDA medium (87 plastic bulbs), and then a sufficient amount of a complete strain was selected and stored in a refrigerator at 4 C until use. In addition, 600 mL of PDB
medium was placed in an Erlenmeyer flask, and then a PDA culture strain was added thereto and shake-cultured for 8 days. Also, a liquid culture medium comprising 1.5 wt% of sugar, 0.5 wt% of glucose, 0.5 wt% of potato starch, 0.25 wt% of soy flour, 0.25 wt%
of sorghum powder, 0.05 wt% of magnesium sulfate (MgSO4), 0.05 wt% of monopotassium phosphate (I<H2PO4), 0.05 wt% of dipotassium phosphate (K2I-fPO4) and 96.85 wt% of water was sterilized for 20 minutes in a 800-L fennenter at 121 C and at an air injection rate of 1.5 kgf/cm2, and then cooled to 23 C, after which it was inoculated with 600 mL of the PDB
culture strain to be used as a starter. Then, Ceriporia lacerata mycelia were liquid-cultured in the medium at a temperature of 23 C, an aeration rate of 0.5-1.5 kgf/cm2 and a carbon dioxide concentration of 1,000-2,000 ppm for 10 days, thereby preparing a Ceriporia lacerata mycelium culture.
1-2. Preparation of Ceriporia lacerata culture extract The prepared Ceriporia lacerata mycelium culture was freeze-dried using a vacuum freeze dryer at a temperature of 25 C for 72 hours to form powder. 5 g of the dried powder was suspended sufficiently in 100 mL of distilled water and then centrifuged at 8,000 rpm for 20 minutes, and a 2-3-fold amount of cold alcohol was added to the supernatant. The resulting solution was placed in a refrigerator at 4 C and allowed to stand for 12 hours. The supernatant in the solution which had been allowed to stand was centrifuged again at 8,000 rpm for 20 minutes, and the precipitate was recovered, thereby extracting a crude exopolysaccharide. The crude exopolysaccharide was dried in a freeze dryer for 72 hours, thereby obtaining a complete exopolysaccharide.
2. Optimization of conditions for liquid culture of Ceriporia lacerata 2-1. Experimental method 2-1-1. Culture conditions For optimization of Ceriporia lacerata liquid culture conditions according to shaking flask culture conditions, physiochemical characteristics depending on kinds and to concentrations of carbohydrates and micronutrients and the contents of the mycelium and exopolysaccharide were measured. For evaluation of characteristics, carbon sources including glucose, sucrose, lactose, fructose and galactose were used at a concentration of 3-5%, and nitrogen sources including tryptone, yeast extract, soy flour, L-glutamic acid, ammonium persulfate, malt extract and peptone were used at a concentration of 0.25%. For micronutrients, KH2PO4, MgSO4, ZnSO4, CuSO4, FeSO4 and CaC12 were used at a concentration of 0.1-0.5%. Culture was carried out in a 1,000 mL Erlenmeyer flask in a total volume of 800 mL at 25 C and 120 rpm for 8 days, followed by analysis.
In a 5 L jar fermenter, culture was carried out in a total volume of 3 L for various periods of time (days), thereby analyzing physicochemical characteristics depending on culture time.
2-1-2. Measurement of pH, acidity and Brix pH was measured with a pH meter, and Brix was measured using an electronic Brix meter. Acidity was measured by measuring the pH of 10 mL of a culture with a pH meter, adding 0.1 N NaOH until the pH of the culture reached 8.3, and then comparing the used amount of 0.1 N NaOH and the content of tartaric acid.
2-1-3. Method for measurement of mycelium and exopolysaccharide contents =
A culture was centrifuged at 12,000 xg for 20 minutes, and the precipitate was washed three times with distilled water and then filtered. The filtrate was freeze-dried and weighed, thereby measuring the production of mycelia. A culture was centrifuged at 12,000 xg for 20 minutes, and a 2-fold volume of cold isopropyl alcohol was added to the supernatant. Then, the solution was incubated at 4 C overnight and centrifuged again at 12,000 xg for 20 minutes. The precipitate was dissolved in distilled water and freeze-dried and weighed, thereby measuring the production of mycelia.
2-1-4. Measurement of tyrosine content and protease, CL-amylase and fibrinolytic enzyme activities In order to measure the production of peptide in a Ceriporia lacerata culture, the content of tyrosine in the culture was measured using folin phenol reagent.
Specifically, 0.7 mL of 0.44 M TCA (trichloroacetic acid) was added to 0.7 mL of the culture and then incubated at 37 C for 30 minutes. The solution was centrifuged at 15,000 rpm for 10 minutes, and the precipitate was removed. 2.5 mL of 0.55 M Na2CO3 and 0.5 mL
of phenol reagent were sequentially added to 1 mL of the collected supernatant and was allowed to react in a water bath at 37 C for 30 minutes. The reaction solution was cooled to room temperature, and then the absorbance at 660 nm was measured using a spectrophotometer (UNION, Kontron Instruments, France).
The titers of a-amylase and protease in the culture were measured based on a-amylase and protease activities. As a substrate for a-amylase, I mL of 1%
soluble starch (0.02 M phosphate buffer, pH 7.0) was used. 1 mL of a pre-prepared enzyme solution was added to the substrate and allowed to react at 37 C for 30 minutes, and the reaction was stopped with 10 mL of 1 M acetic acid. 2 mL of an iodide solution (0.005%
12+0.05% KI) was added to the reaction solution, and the absorbance at 660 nm was measured.
A
decrease in blank OD of 10% was taken as 1 unit, and the result was expressed in terms of 1 g of the sample. As a control blank, a deactivated solution obtained by boiling a pre-prepared enzyme solution at 100 C for 30 minutes was used.
=
=
To measure the activity of protease, 0.35 mL of 0.6% casein solution as a substrate and 0.35 mL of the enzyme solution were placed in an e-tube and allowed to react in a water bath 37 C for 10 minutes, and then 0.7 mL of 0.44 M TCA solution was added thereto to stop the reaction. The reaction solution was allowed to stand at 37 C for 30 minutes. The reaction solution was centrifuged at 15,000 rpm for 15 minutes, and then 2.5 mL of 0.55 M
Na2CO3 and 0.5 mL of 3-fold-diluted folin reagent were added to 1 mL of the filtrate and then allowed to react at 37 C for 30 minutes. Then, the absorbance at 660 nm was measured. The enzyme amount that liberates 1 g of tyrosine for 1 minute under such reaction conditions was taken as 1 unit.
The activity of fibrinolytic enzyme was measured using the Astrup and Mllerz method that is a kind of fibrin plate method. Specifically, 10 mL of a solution of 0.5%
fibrinogen in 0.067 M sodium phosphate buffer (pH 7.4) was added to a 9 cm-diameter Petri dish. To the solution, 0.1 mL of a solution of thrombin (100 units/mL) in 0.067 M sodium phosphate buffer (pH 7.4) was added and mixed rapidly, and the mixture was allowed to stand at room temperature for 30 minutes so as to be solidified. 20 L of the culture was dropped onto each marked position of the Fibrin plate and allowed to react at 37 C for 2 hours, and then the enzyme activity was determined by the dissolution area.
The standard curve of standard plasmin enzyme activity was plotted, and the fibrinolytic enzyme activity (%) of the culture was expressed as plasmin units in comparison with the standard curve.
As a control, the purified fibrinolytic enzyme plasmin (5 units/mL) was used.
2-1-5. Measurement of sugar and protein contents The sugar content was measured by the phenol-sulfuric acid method.
Specifically, the sugar content was determined by adding 25 j.tL of 80% phenol to 1 mL of a sample diluted at various concentrations, adding 2.5 mL of sulfuric acid thereto, cooling the mixture to room temperature, and measuring the absorbance at 425 nm. The protein content was measured by the BCA method using bovine serum albumin as a standard.
=
2-1-6. Measurement of molecular weight of exopolysaccharide (EPS) by GPC
The dry viscous substance was dissolved in 0.1 M Na2SO4/0.05 M NaN3 solution (adjusted to pH 4 with glacial acetic acid) at a concentration of 1%, and the solution was centrifuged. The supernatant was filtered through a 0.45 um syringe filter and analyzed by GPC (Gel Permeation Chromatography) under the following conditions: detector:
RI; GPC
column: Shodex SB 805 HQ (Japan); mobile phase: 0.1 M Na2SO4/0.05 M NaN3 (adjusted to pH 4 with glacial acetic acid); and flow rate: 1.0 mL/min. A standard curve was plotted using dextran (American Polymer Corporation, USA) having different molecular weights (130, 400, 770 and 1,200 kDa), and the molecular weight of EPS was measured using a refractive index meter (Table 1).
Table 1 Determination of Molecular weight HPLC System Knauer K-501 system Column 0Hpak SB 805 HQ (Shodex, Japan) Mobile phase 0.1 M Na2SO4/0.05 M NaN3/pH 4 Flow rate 1.0 mL/min Detector RI (Knauer K-2310) 2-2. Experimental results 2-2-1. Sequencing of Ceriporia lacerata 1TS-5.8S rDNA
ITS-5.8S rDNA sequencing of the Ceriporia lacerata strain showed that the strain has a sequence homology of 92% with Ceriporia lacerata FJ462746 (FIG. 1).
2-2-2. Evaluation of physiochemical characteristics depending on the kind and concentration of sugar To evaluate physiochemical characteristics depending on the kind of sugar, each of five kinds of sugar (lactose, sucrose, glucose, fructose and galactose) was added to a culture . .
at a concentration of 3% and incubated for 7 days. As a result, it was found that there was no significant difference in pH among the sugars, and residual sugar was slightly low in the case of glucose. Also, it was shown that since the shape and size of mycelial pellets changed depending on the kind of carbon source, the influence of the carbon source on mycelial growth is very significant. Also, the mycelium and EPS contents were higher in the order of glucose, fructose and sucrose. Glucose was added at various concentrations up to 15%, and the mycelium and EPS content were measured. As a result, the contents increased in a concentration-dependent manner up to 3%, and did not significantly change over 3%. Thus, a glucose concentration of 3% was chosen as an optimal condition.
2-2-3. Evaluation of physiochemical characteristics depending on the kind and concentration of nitrogen sources In order to evaluate physiochemical characteristics depending on the kind of nitrogen sources, each of 7 kinds of nitrogen sources (tryptone, yeast extract, soy flour, L-glutamic acid, ammonium persulfate, malt extract and peptone) was added at a concentration of 3% and incubated for 7 days. The mycelium content was the highest in the case of soy flour, and the EPS content was high in the cases of tryptone, yeast extract, soy flour and L-glutamic acid at similar levels. However, in economical and industrial terms, soy flour showing high mycelium and EPS contents was selected as a nitrogen source. When soy flour was added at a concentration of 0.25%, there was no great change in the pH of the culture, and the Brix of the culture increased in a manner dependent on the concentration of soy flour. The tyrosine content of the culture also increased in a manner dependent on the concentration of soy flour, and the protease and alpha-amylase activities were high at a soy flour concentration of 2-3% and slightly decreased at higher soy flour concentrations.
However, the fibrinolytic enzyme activity increased in a manner dependent on the concentration of soy flour. The mycelium and EPS contents showed a tendency to increase up to a soy flour concentration of 3% and did not significantly change at a soy flour concentration of more than 3%, like the case of the carbon source concentration. Thus, the =
optimal soy flour concentration was chosen to be 3%. The contents of sugar and protein in the EPS of the culture cultured in the presence of soy flour were measured. As a result, the sugar content was about 40% and the protein was about 33%, suggesting that the EPS is a polysaccharide composed of sugar bonded with protein. Table 2 below shows chemical characteristics and enzyme activities depending on the content of soy flour, and Table 3 below shows the composition of exopolysaccharide depending on the content of soy flour.
Table 2 Soy pH "Brix Tyrosine Protease a-amylase Fibrinolytic flour content(mg% activitruni activity(unit/ enzyme t/mL) IT1L ) activity(unit/m L) 0.2 4.25 3.0 7.46 0.04 5.77 0,60 1 4,47 3.9 30.12 0.17 3.64 0.60 4.59 4.8 48.37 0.75 6.78 0.75 3 4.74 5.5 64.21 1.02 1.68 0.85 4 4.91 6.3 69.39 0.94 1.10 0.75 5 4.84 7.0 82.32 0.75 0.60 1.25 Table 3 Soy flour Total sugar content(%) Total protein content(%) 0.2 50.24 1.06 33.13 0.30 1 47.94 0.15 32.49 1.01 2 42.78 0.08 37.91 0.01 3 40.57 0.68 33.34 1.41 4 38.46 0.09 34.34 0.20 5 32.63 0.30 36.20-1-0.81 2-2-4. Evaluation of physicochemical characteristics depending on the kind and concentration of micronutrients = .
In order to evaluate physicochemical characteristics depending on the kind of micronutrients, each of five kinds of micronutrients (KH2PO4, MgSO4, ZnSO4, CuSO4, FeSO4, and CaC12) was added at a concentration of 0.5% and incubated for 7 days. As a result, the mycelium content was the highest in the case of CuSO4, but the EPS
production was the highest in the case of Mg504, and thus Mg504was selected as a micronutrient. In addition, the micronutrient was added at various concentration of 0-0.25%, and the mycelium and EPS contents were measured. As a result, the contents increased up to a micronutrient concentration of 0.15%, but did not significantly change at a concentration of 0.22%. Thus, the optimal concentration of the micronutrient was chosen to be 0.15%.
2-2-5. Evaluation of physicochemical characteristics depending on culture time (5 L
jar fermenter) Culture was performed in a 5-L jar fermenter using the selected optimal medium while the mycelium and EPS contents were measured at various points of time.
As a result, the mycelium content did not significantly change up to 8 days of culture, but showed a decrease after 10 days of culture, and the EPS content showed a tendency to increase after 8 days, but this increase was not significant. Thus, the optimal culture time was chosen to be 8 days.
2-2-6. Evaluation of exopolysaccharide (EPS) characteristics EPS was subjected to secondary purification and treated with protease, and the protein and sugar contents thereof were measured. As a result, purification of EPS showed a decrease in the sugar content and an increase in the protein. In addition, the molecular weight of EPS was measured by GPC, and as a result, the molecular weight of EPS was about 120 kDa and was slightly decreased by treatment with protease.
3. Verification of anti-diabetic effects of CLD and EPS in Type 2 diabetes model 3-1. Experimental method 3-1-1. Ceriporia lacerata culture extract The Ceriporia lacerata culture extract used in this experiment was one prepared in the above Example 1.
3-1-2. Method for measurement of mycelium and exopolysaccharide contents The freeze-dried culture was prepared into a 10% solution which was then centrifuged at 8,000 rpm for 20 minutes, and the supernatant was isolated. A 4-fold volume of cold isopropyl alcohol was added to the isolated supernatant and incubated at 4 C
overnight. Then, the solution was centrifuged again at 10,000 rpm for 20 minutes, and the precipitate was collected and weighed to determine the content of the marker substance exopolysaccharide. It was shown that the major component of the Ceriporia lacerata culture was a carbohydrate. The crude carbohydrate content was about 79% and the crude protein content was about 15%.
3-1-3. Experimental animal and experimental design In order to examine the blood glucose lowering effects of the Ceriporia lacerata culture and exopolysaccharide, C57BL/Ksj (BL/Ls) homozygous diabetic (db/db) mice (SPF) as a typical Type 2 diabetes animal model were used in this experiment. db/db mice are animals in which diabetes is caused by a point mutation in the leptin receptor gene Lepr of chromosome 4. In the animals, as the leptin receptor decreases, the signal transduction ability decreases, and thus the blood glucose level increases. The animals are recognized as an insulin-independent diabetes model and suitable for the evaluation and comparison of experimental results on the basis of raw data. The db/db mice used in this study were 6-week-old male mice weighing about 30-40 g, and these mice were produced in Japan SLC
Inc. and obtained from Central Laboratory Animal (Korea). The mice were acclimated for about 7 days, and the weight and blood glucose level thereof were measured. 30 healthy animals suitable for experimentation and having no abnormal general conditions were selected.
. .
The experimental animals were divided according to a randomized block design into a negative control group, an exopolysaccharide low-dose group (150 mg/kg), an exopolysaccharide high-dose group (300 mg/kg) and a positive control group (metformin-300 mg/kg) such that the blood glucose level and weight are equal among the groups.
These mice were reared for 6 weeks. In addition, normal and control groups, each consisting of 6 animals, were kept for 6 weeks under the same conditions. All test substances and positive control substances were orally administered at the same point of time every day, and the normal and negative control groups were orally administered with water (FIG. 11). During the rearing period of 6 week, a change in the weight was measured once weekly. In order to examine a change in the blood glucose level, the tail vein blood glucose level was measured using ACCU-CHEK Sensor (Germany) once weekly after 12-hr fasting.
The experimental animals were fed with a commercially available animal solid feed (Samtaco Co. Ltd., Korea) and allowed to access water ad libitum. The animals were reared under the conditions of temperature of 23 3 C and relative humidity of 50 +
medium was placed in an Erlenmeyer flask, and then a PDA culture strain was added thereto and shake-cultured for 8 days. Also, a liquid culture medium comprising 1.5 wt% of sugar, 0.5 wt% of glucose, 0.5 wt% of potato starch, 0.25 wt% of soy flour, 0.25 wt%
of sorghum powder, 0.05 wt% of magnesium sulfate (MgSO4), 0.05 wt% of monopotassium phosphate (I<H2PO4), 0.05 wt% of dipotassium phosphate (K2I-fPO4) and 96.85 wt% of water was sterilized for 20 minutes in a 800-L fennenter at 121 C and at an air injection rate of 1.5 kgf/cm2, and then cooled to 23 C, after which it was inoculated with 600 mL of the PDB
culture strain to be used as a starter. Then, Ceriporia lacerata mycelia were liquid-cultured in the medium at a temperature of 23 C, an aeration rate of 0.5-1.5 kgf/cm2 and a carbon dioxide concentration of 1,000-2,000 ppm for 10 days, thereby preparing a Ceriporia lacerata mycelium culture.
1-2. Preparation of Ceriporia lacerata culture extract The prepared Ceriporia lacerata mycelium culture was freeze-dried using a vacuum freeze dryer at a temperature of 25 C for 72 hours to form powder. 5 g of the dried powder was suspended sufficiently in 100 mL of distilled water and then centrifuged at 8,000 rpm for 20 minutes, and a 2-3-fold amount of cold alcohol was added to the supernatant. The resulting solution was placed in a refrigerator at 4 C and allowed to stand for 12 hours. The supernatant in the solution which had been allowed to stand was centrifuged again at 8,000 rpm for 20 minutes, and the precipitate was recovered, thereby extracting a crude exopolysaccharide. The crude exopolysaccharide was dried in a freeze dryer for 72 hours, thereby obtaining a complete exopolysaccharide.
2. Optimization of conditions for liquid culture of Ceriporia lacerata 2-1. Experimental method 2-1-1. Culture conditions For optimization of Ceriporia lacerata liquid culture conditions according to shaking flask culture conditions, physiochemical characteristics depending on kinds and to concentrations of carbohydrates and micronutrients and the contents of the mycelium and exopolysaccharide were measured. For evaluation of characteristics, carbon sources including glucose, sucrose, lactose, fructose and galactose were used at a concentration of 3-5%, and nitrogen sources including tryptone, yeast extract, soy flour, L-glutamic acid, ammonium persulfate, malt extract and peptone were used at a concentration of 0.25%. For micronutrients, KH2PO4, MgSO4, ZnSO4, CuSO4, FeSO4 and CaC12 were used at a concentration of 0.1-0.5%. Culture was carried out in a 1,000 mL Erlenmeyer flask in a total volume of 800 mL at 25 C and 120 rpm for 8 days, followed by analysis.
In a 5 L jar fermenter, culture was carried out in a total volume of 3 L for various periods of time (days), thereby analyzing physicochemical characteristics depending on culture time.
2-1-2. Measurement of pH, acidity and Brix pH was measured with a pH meter, and Brix was measured using an electronic Brix meter. Acidity was measured by measuring the pH of 10 mL of a culture with a pH meter, adding 0.1 N NaOH until the pH of the culture reached 8.3, and then comparing the used amount of 0.1 N NaOH and the content of tartaric acid.
2-1-3. Method for measurement of mycelium and exopolysaccharide contents =
A culture was centrifuged at 12,000 xg for 20 minutes, and the precipitate was washed three times with distilled water and then filtered. The filtrate was freeze-dried and weighed, thereby measuring the production of mycelia. A culture was centrifuged at 12,000 xg for 20 minutes, and a 2-fold volume of cold isopropyl alcohol was added to the supernatant. Then, the solution was incubated at 4 C overnight and centrifuged again at 12,000 xg for 20 minutes. The precipitate was dissolved in distilled water and freeze-dried and weighed, thereby measuring the production of mycelia.
2-1-4. Measurement of tyrosine content and protease, CL-amylase and fibrinolytic enzyme activities In order to measure the production of peptide in a Ceriporia lacerata culture, the content of tyrosine in the culture was measured using folin phenol reagent.
Specifically, 0.7 mL of 0.44 M TCA (trichloroacetic acid) was added to 0.7 mL of the culture and then incubated at 37 C for 30 minutes. The solution was centrifuged at 15,000 rpm for 10 minutes, and the precipitate was removed. 2.5 mL of 0.55 M Na2CO3 and 0.5 mL
of phenol reagent were sequentially added to 1 mL of the collected supernatant and was allowed to react in a water bath at 37 C for 30 minutes. The reaction solution was cooled to room temperature, and then the absorbance at 660 nm was measured using a spectrophotometer (UNION, Kontron Instruments, France).
The titers of a-amylase and protease in the culture were measured based on a-amylase and protease activities. As a substrate for a-amylase, I mL of 1%
soluble starch (0.02 M phosphate buffer, pH 7.0) was used. 1 mL of a pre-prepared enzyme solution was added to the substrate and allowed to react at 37 C for 30 minutes, and the reaction was stopped with 10 mL of 1 M acetic acid. 2 mL of an iodide solution (0.005%
12+0.05% KI) was added to the reaction solution, and the absorbance at 660 nm was measured.
A
decrease in blank OD of 10% was taken as 1 unit, and the result was expressed in terms of 1 g of the sample. As a control blank, a deactivated solution obtained by boiling a pre-prepared enzyme solution at 100 C for 30 minutes was used.
=
=
To measure the activity of protease, 0.35 mL of 0.6% casein solution as a substrate and 0.35 mL of the enzyme solution were placed in an e-tube and allowed to react in a water bath 37 C for 10 minutes, and then 0.7 mL of 0.44 M TCA solution was added thereto to stop the reaction. The reaction solution was allowed to stand at 37 C for 30 minutes. The reaction solution was centrifuged at 15,000 rpm for 15 minutes, and then 2.5 mL of 0.55 M
Na2CO3 and 0.5 mL of 3-fold-diluted folin reagent were added to 1 mL of the filtrate and then allowed to react at 37 C for 30 minutes. Then, the absorbance at 660 nm was measured. The enzyme amount that liberates 1 g of tyrosine for 1 minute under such reaction conditions was taken as 1 unit.
The activity of fibrinolytic enzyme was measured using the Astrup and Mllerz method that is a kind of fibrin plate method. Specifically, 10 mL of a solution of 0.5%
fibrinogen in 0.067 M sodium phosphate buffer (pH 7.4) was added to a 9 cm-diameter Petri dish. To the solution, 0.1 mL of a solution of thrombin (100 units/mL) in 0.067 M sodium phosphate buffer (pH 7.4) was added and mixed rapidly, and the mixture was allowed to stand at room temperature for 30 minutes so as to be solidified. 20 L of the culture was dropped onto each marked position of the Fibrin plate and allowed to react at 37 C for 2 hours, and then the enzyme activity was determined by the dissolution area.
The standard curve of standard plasmin enzyme activity was plotted, and the fibrinolytic enzyme activity (%) of the culture was expressed as plasmin units in comparison with the standard curve.
As a control, the purified fibrinolytic enzyme plasmin (5 units/mL) was used.
2-1-5. Measurement of sugar and protein contents The sugar content was measured by the phenol-sulfuric acid method.
Specifically, the sugar content was determined by adding 25 j.tL of 80% phenol to 1 mL of a sample diluted at various concentrations, adding 2.5 mL of sulfuric acid thereto, cooling the mixture to room temperature, and measuring the absorbance at 425 nm. The protein content was measured by the BCA method using bovine serum albumin as a standard.
=
2-1-6. Measurement of molecular weight of exopolysaccharide (EPS) by GPC
The dry viscous substance was dissolved in 0.1 M Na2SO4/0.05 M NaN3 solution (adjusted to pH 4 with glacial acetic acid) at a concentration of 1%, and the solution was centrifuged. The supernatant was filtered through a 0.45 um syringe filter and analyzed by GPC (Gel Permeation Chromatography) under the following conditions: detector:
RI; GPC
column: Shodex SB 805 HQ (Japan); mobile phase: 0.1 M Na2SO4/0.05 M NaN3 (adjusted to pH 4 with glacial acetic acid); and flow rate: 1.0 mL/min. A standard curve was plotted using dextran (American Polymer Corporation, USA) having different molecular weights (130, 400, 770 and 1,200 kDa), and the molecular weight of EPS was measured using a refractive index meter (Table 1).
Table 1 Determination of Molecular weight HPLC System Knauer K-501 system Column 0Hpak SB 805 HQ (Shodex, Japan) Mobile phase 0.1 M Na2SO4/0.05 M NaN3/pH 4 Flow rate 1.0 mL/min Detector RI (Knauer K-2310) 2-2. Experimental results 2-2-1. Sequencing of Ceriporia lacerata 1TS-5.8S rDNA
ITS-5.8S rDNA sequencing of the Ceriporia lacerata strain showed that the strain has a sequence homology of 92% with Ceriporia lacerata FJ462746 (FIG. 1).
2-2-2. Evaluation of physiochemical characteristics depending on the kind and concentration of sugar To evaluate physiochemical characteristics depending on the kind of sugar, each of five kinds of sugar (lactose, sucrose, glucose, fructose and galactose) was added to a culture . .
at a concentration of 3% and incubated for 7 days. As a result, it was found that there was no significant difference in pH among the sugars, and residual sugar was slightly low in the case of glucose. Also, it was shown that since the shape and size of mycelial pellets changed depending on the kind of carbon source, the influence of the carbon source on mycelial growth is very significant. Also, the mycelium and EPS contents were higher in the order of glucose, fructose and sucrose. Glucose was added at various concentrations up to 15%, and the mycelium and EPS content were measured. As a result, the contents increased in a concentration-dependent manner up to 3%, and did not significantly change over 3%. Thus, a glucose concentration of 3% was chosen as an optimal condition.
2-2-3. Evaluation of physiochemical characteristics depending on the kind and concentration of nitrogen sources In order to evaluate physiochemical characteristics depending on the kind of nitrogen sources, each of 7 kinds of nitrogen sources (tryptone, yeast extract, soy flour, L-glutamic acid, ammonium persulfate, malt extract and peptone) was added at a concentration of 3% and incubated for 7 days. The mycelium content was the highest in the case of soy flour, and the EPS content was high in the cases of tryptone, yeast extract, soy flour and L-glutamic acid at similar levels. However, in economical and industrial terms, soy flour showing high mycelium and EPS contents was selected as a nitrogen source. When soy flour was added at a concentration of 0.25%, there was no great change in the pH of the culture, and the Brix of the culture increased in a manner dependent on the concentration of soy flour. The tyrosine content of the culture also increased in a manner dependent on the concentration of soy flour, and the protease and alpha-amylase activities were high at a soy flour concentration of 2-3% and slightly decreased at higher soy flour concentrations.
However, the fibrinolytic enzyme activity increased in a manner dependent on the concentration of soy flour. The mycelium and EPS contents showed a tendency to increase up to a soy flour concentration of 3% and did not significantly change at a soy flour concentration of more than 3%, like the case of the carbon source concentration. Thus, the =
optimal soy flour concentration was chosen to be 3%. The contents of sugar and protein in the EPS of the culture cultured in the presence of soy flour were measured. As a result, the sugar content was about 40% and the protein was about 33%, suggesting that the EPS is a polysaccharide composed of sugar bonded with protein. Table 2 below shows chemical characteristics and enzyme activities depending on the content of soy flour, and Table 3 below shows the composition of exopolysaccharide depending on the content of soy flour.
Table 2 Soy pH "Brix Tyrosine Protease a-amylase Fibrinolytic flour content(mg% activitruni activity(unit/ enzyme t/mL) IT1L ) activity(unit/m L) 0.2 4.25 3.0 7.46 0.04 5.77 0,60 1 4,47 3.9 30.12 0.17 3.64 0.60 4.59 4.8 48.37 0.75 6.78 0.75 3 4.74 5.5 64.21 1.02 1.68 0.85 4 4.91 6.3 69.39 0.94 1.10 0.75 5 4.84 7.0 82.32 0.75 0.60 1.25 Table 3 Soy flour Total sugar content(%) Total protein content(%) 0.2 50.24 1.06 33.13 0.30 1 47.94 0.15 32.49 1.01 2 42.78 0.08 37.91 0.01 3 40.57 0.68 33.34 1.41 4 38.46 0.09 34.34 0.20 5 32.63 0.30 36.20-1-0.81 2-2-4. Evaluation of physicochemical characteristics depending on the kind and concentration of micronutrients = .
In order to evaluate physicochemical characteristics depending on the kind of micronutrients, each of five kinds of micronutrients (KH2PO4, MgSO4, ZnSO4, CuSO4, FeSO4, and CaC12) was added at a concentration of 0.5% and incubated for 7 days. As a result, the mycelium content was the highest in the case of CuSO4, but the EPS
production was the highest in the case of Mg504, and thus Mg504was selected as a micronutrient. In addition, the micronutrient was added at various concentration of 0-0.25%, and the mycelium and EPS contents were measured. As a result, the contents increased up to a micronutrient concentration of 0.15%, but did not significantly change at a concentration of 0.22%. Thus, the optimal concentration of the micronutrient was chosen to be 0.15%.
2-2-5. Evaluation of physicochemical characteristics depending on culture time (5 L
jar fermenter) Culture was performed in a 5-L jar fermenter using the selected optimal medium while the mycelium and EPS contents were measured at various points of time.
As a result, the mycelium content did not significantly change up to 8 days of culture, but showed a decrease after 10 days of culture, and the EPS content showed a tendency to increase after 8 days, but this increase was not significant. Thus, the optimal culture time was chosen to be 8 days.
2-2-6. Evaluation of exopolysaccharide (EPS) characteristics EPS was subjected to secondary purification and treated with protease, and the protein and sugar contents thereof were measured. As a result, purification of EPS showed a decrease in the sugar content and an increase in the protein. In addition, the molecular weight of EPS was measured by GPC, and as a result, the molecular weight of EPS was about 120 kDa and was slightly decreased by treatment with protease.
3. Verification of anti-diabetic effects of CLD and EPS in Type 2 diabetes model 3-1. Experimental method 3-1-1. Ceriporia lacerata culture extract The Ceriporia lacerata culture extract used in this experiment was one prepared in the above Example 1.
3-1-2. Method for measurement of mycelium and exopolysaccharide contents The freeze-dried culture was prepared into a 10% solution which was then centrifuged at 8,000 rpm for 20 minutes, and the supernatant was isolated. A 4-fold volume of cold isopropyl alcohol was added to the isolated supernatant and incubated at 4 C
overnight. Then, the solution was centrifuged again at 10,000 rpm for 20 minutes, and the precipitate was collected and weighed to determine the content of the marker substance exopolysaccharide. It was shown that the major component of the Ceriporia lacerata culture was a carbohydrate. The crude carbohydrate content was about 79% and the crude protein content was about 15%.
3-1-3. Experimental animal and experimental design In order to examine the blood glucose lowering effects of the Ceriporia lacerata culture and exopolysaccharide, C57BL/Ksj (BL/Ls) homozygous diabetic (db/db) mice (SPF) as a typical Type 2 diabetes animal model were used in this experiment. db/db mice are animals in which diabetes is caused by a point mutation in the leptin receptor gene Lepr of chromosome 4. In the animals, as the leptin receptor decreases, the signal transduction ability decreases, and thus the blood glucose level increases. The animals are recognized as an insulin-independent diabetes model and suitable for the evaluation and comparison of experimental results on the basis of raw data. The db/db mice used in this study were 6-week-old male mice weighing about 30-40 g, and these mice were produced in Japan SLC
Inc. and obtained from Central Laboratory Animal (Korea). The mice were acclimated for about 7 days, and the weight and blood glucose level thereof were measured. 30 healthy animals suitable for experimentation and having no abnormal general conditions were selected.
. .
The experimental animals were divided according to a randomized block design into a negative control group, an exopolysaccharide low-dose group (150 mg/kg), an exopolysaccharide high-dose group (300 mg/kg) and a positive control group (metformin-300 mg/kg) such that the blood glucose level and weight are equal among the groups.
These mice were reared for 6 weeks. In addition, normal and control groups, each consisting of 6 animals, were kept for 6 weeks under the same conditions. All test substances and positive control substances were orally administered at the same point of time every day, and the normal and negative control groups were orally administered with water (FIG. 11). During the rearing period of 6 week, a change in the weight was measured once weekly. In order to examine a change in the blood glucose level, the tail vein blood glucose level was measured using ACCU-CHEK Sensor (Germany) once weekly after 12-hr fasting.
The experimental animals were fed with a commercially available animal solid feed (Samtaco Co. Ltd., Korea) and allowed to access water ad libitum. The animals were reared under the conditions of temperature of 23 3 C and relative humidity of 50 +
10% with a 12-hr light/12-hr dark cycle (lighting: 8 a.m. to 8 p.m.).
3-1-4. Oral glucose tolerance test (OGTT) The animals were fasted for 12 hours or more, and the fasting blood glucose level was measured. Each of samples obtained by dissolving each of the Ceriporia lacerata powder and EPS in distilled water at various concentrations was administered orally to five animals of each group. The control group was administered with the same amount of saline.
Next, the groups other than the control group were orally administered with 40% glucose at a dose of 2 g/kg bw, and blood was collected from the tail vein at 30, 60, 90 and 120 minutes after glucose administration to observe a change in the blood glucose level.
The increase in the blood glucose level at each point of time was calculated to plot a blood glucose curve.
3-1-5. Sacrifice of experimental animals and sampling Blood glucose levels should be measured in tail veins after 12-hr fasting, and blood for biochemical analysis should be collected after fasting of 12 hours or more. Thus, the sacrifice of the experimental animals was performed 2 days after 6th blood glucose level measurement at 6 weeks after the start of rearing.
For sacrifice of the experimental animals, all the animals were fasted for 12 hours and anesthetized with ether. Blood was taken from the saphenous vein and placed in a tube for serum separation. Then, the blood was centrifuged at 3,000 rpm for 20 minutes to obtain serum which was to be used as a sample for analysis of biochemical markers.
Immediately after sacrifice, the liver, abdominal fat and the like were extracted from all the to animals, weighed, fast-frozen at -80 C and stored until use. Portions of the extracted liver and pancreas were fixed in 4% paraformaldehyde solution and subjected to histological analysis.
3-1-6. Serum c-peptide, insulin and leptin levels The serum c-peptide, insulin and leptin levels that are blood glucose-related functional indices were measured from the serum (collected from the saphenous vein) using double antibody C-peptide (DPC, USA), an insulin RIA kit (DPC, USA), and a mouse leptin RLA kit (L1NCO, USA), respectively, by a radioimmunoassay.
3-2. Experimental results 3-2-1. Changes in food intake and weight FIGs. 14, 15 and 16 show the changes in weight, food intake and water intake of the experimental animals for 6 weeks. The initial bodyweights of the diabetes control group and the EPS-administered group were similar (about 32 g). Also, there was no significant difference in bodyweight after 6 weeks between the diabetes control group and the test groups, and the bodyweig,ht showed a tendency to increase throughout the experimental period. The feed and water intakes were higher in the diabetes control group than in the . .
normal control group, and the water and feed intakes of the positive control group MET300 were significantly lower than those of other groups.
3-2-2. Organ weight The weights of liver, kidney, spleen, kidney fat and abdominal fat of the experimental animals were measured, and the results of the measurement are shown in Table 4 below.
Table 4 Liver Kidney Spleen Kidney fat Abdominal fat (W/BW) (W/BW) (W/BW) (W/BW) (W/BW) NC 0.94 0.14 0.29 0.03 0.06 0.01 0.12 0.04 0.43 0.17 DM 2.89 0.04 0.41 0.06 0.04 0.02 0.82 0.17 2.34 0.28 DM-EX0150 2.50 0.29 0.39 + 0.05 0.06 0.03 0.63 0.12 2.48 0.14 DM-EX0300 2.65 0.05 0.40 0.04 0.05 + 0.02 0.55 0.17 2.55 0.15 DM-MET300 2.60 + 0.19 0.39 0.03 0.03 0.02 0.89 0.13 2.564 0.33 DM-ALL300 2.50 0.27 0.40 + 0.03 0.06 0.01 0.48 + 0.12 2.41 + 0.21 The liver weight showed a tendency to increase rapidly in the diabetes-induced group and showed a tendency to significantly decrease in the groups administered with the sample. These results are consistent with the report that fat is accumulated in the liver upon the induction of diabetes to increase the liver volume. With respect to the kidney, it is known that the kidney volume increases with an increase in glomerular filtration rate in the initial stage of development of diabetes. In this study, the weight of the kidney also showed a tendency to increase, but this increase was not significant. In addition, the weight of the spleen did not significantly differ among the groups. The weight of the kidney fat increased rapidly in the diabetes-induced group, but was significantly decreased by administration of =
EPS and Ceriporia lacerata powder. In addition, the weight of the abdominal fat did not significantly differ among the groups.
3-2-3. Effect on change in blood glucose level FIG. 16 shows the results of measuring the change in blood glucose levels after 12-hr fasting. The initial blood glucose level was similar (about 150 mg/dL) -among the groups, but started to increase slightly from one week after administration of the sample. After 3 weeks, the blood glucose level increased rapidly so that the diabetes control group showed a blood glucose level of about 400 mg/dL, whereas the metformin group showed no increase in to the blood glucose level. After that, the blood glucose level continued to increase, but the groups administered with EPS and Ceriporia lacerata powder showed a significant decrease in the blood glucose level compared to the diabetes control group.
3-2-4. Oral glucose tolerance The oral glucose tolerance of EPS and Ceriporia lacerata powder was measured at 6 week of sample administration, and the results of the measurement are shown in FIG. 17.
The diabetes control group showed a blood glucose level of 600 mg/dL which is the highest value measurable by the blood glucose meter, and it maintained high blood glucose levels throughout the glucose tolerance test. On the other hand, the group administered with EPS
and Ceriporia lacerata powder showed an initial fasting blood glucose level of 500 mg/dL
which was significantly lower than that of the diabetes control group.
However, the blood glucose level of the group administered with EPS and Ceriporia lacerata powder increased gradually with the passage of time and was 600 mg/dL (the highest value measurable by the blood glucose meter) after 30 minutes. Thereafter, the blood glucose level gradually decreased, and after 180 minutes, the blood glucose level was restored to 520 mg/dL which was similar to the initial blood glucose level.
3-2-5. Blood glucose level The blood glucose levels of the animals sacrificed after 6-week oral administration of EPS were measured. As a result, it was shown that the blood glucose level of the DM group increased to about 900 mg/dL, whereas the blood glucose levels of the groups administered with the sample decreased in a manner dependent on the concentration of the sample.
Specifically, the blood glucose level of the EPS 300 group decreased to about 700 mg/dL, suggesting that EPS plays a positive role in lowering blood glucose levels.
3-2-6. Effect on serum lipid levels The serum lipid levels of the animals sacrificed after 6-week oral administration of EPS were measured. As a result, it was shown that the total cholesterol and triglyceride levels were about two times higher in the DM group than in the NC group, but were significantly lowered in the group administered with EPS. In addition, the group administered with EPS showed a significant increase in the HDL cholesterol and a significant decrease in the LDL-cholesterol level, indicating that EPS is a substance that reduces serum lipid levels in Type 2 diabetes models without changing the bodyweight.
3-2-7. Effects on insulin, C-peptide and leptin levels The serum insulin, C-peptide and leptin levels of the animals sacrificed after 6-week oral administration of EPS were measured. As a result, it was shown that the insulin level did not significantly differ among the groups, and the C-peptide level was higher in the sample-administered groups than in the DM group, suggesting that EPS activates insulin secretion in the pancreas. In addition, the leptin level also increased in the sample-administered groups, suggesting that EPS plays a positive role in insulin resistance.
4. Effect of exopolysaccharide on insulin signal transduction in 3T3-L1 cells 4-1. Experimental method 4-1-1. Cell culture , 3T3-L1 fibroblasts that are preadipocytes have well established biological properties and differentiate into adipocytes when they are cultured under suitable conditions. These cells are used in studies on lipolysis inhibition or lipogenesis in the metabolic process of adipocytes. In addition, adipocytes that are insulin target cells are frequently used in studies on insulin signal transduction. The 3T3-L1 fibroblasts used in the experiment were obtained from the Korean Cell Line Bank and were cultured in Dulbecco's Modified Eagle's Medium (DMEM, GibcoBRL) (containing 10% fetal bovine serum (FBS, GibcoBRL), mM glutaMAX (GibcoBRL), penicillin (10,000 units/mL, Sigma), streptomycin (10 mg/mL, Sigma) under the conditions of 37 C and 10% CO2 while the medium was replaced with high-glucose medium at 3-day intervals. When the 3T3-L1 fibroblasts reached a confluence of 60-80%, the cultured cells were washed with Dulbecco's phosphate buffered saline (PBS, GibcoBRL). These cells were subcultured in a 75 cm2 flask containing 500 lit of 2.5%
trypsin (GibcoBRL) at 37 C for 5 minutes, after which the cells were detached from the flask.
The detached cells were transferred into a fresh flask containing 15 mL of a high-glucose DMEM medium supplemented with 10% FBS.
4-1-2. Glucose uptake into adipocytes 3T3-L1 fibroblasts were cultured to confluence in the same manner as the above cell culture. 2 days after confluence, the cells were cultured for 3 days in a high-glucose DMEM medium containing 0.5 mM 3-isobuty1-1-methyl-xanthine (1BMX, Sigma), 25 jM
dexamethasone (DEX, Sigma) and insulin (Sigma) which are differentiation inducers, and the medium was replaced with a fresh medium at 2-day intervals, whereby the cells were converted to adipocytes. Between 10 days and 15 days during which the preadipocytes were completely converted to adipocytes, a glucose uptake test was performed.
In the glucose uptake test that reflects insulin sensitivity, the 3T3-L1 cells that had been completely converted to adipocytes were treated with 2.5% typsine, and then seeded into a 24-well plate at a concentration of 20x 104 cells/mL as counted by a hemacytometer. The medium was replaced with a low-glucose DMEM medium to starve the cells. The adipocytes in the well plate were washed with PBS and then incubated with a HEPES solution containing 0.1%
bovine serum albumin (BSA, Roche), each of 1 pg/mL and 10 Rg/mL of the Ceriporia lacerata culture extract and insulin at 37 C for 1.5 hours. Then, 10 Ci/mL of the glucose analogue, 2-deoxy-D-[31-1] glucose (2-DG), was added to the cells which were then incubated at 37 C for 10 minutes. After 10 minutes, the cells were washed five times with PBS, lysed with 1N NaOH and neutralized with 1N HC1. The amount of 3H uptake into the cells was measured with a beta-counter (Tri-Carb 21001R, Packard Bioscince, FL) for 5 minutes. In order to eliminate non-specific glucose uptake, cells incubated with cytochalasin B (Sigma) that inhibits the activity of glucose transporter 4 (GLUT4) was also measured.
In the process of examining whether an insulin-sensitive component is contained in the Ceriporia lacerata culture, low-concentration insulin was chosen to be 1 ng/mL and high-concentration insulin was chosen to be 25 ng/mL, because insulin uptake into the cells was the highest at an insulin concentration of 50 ng/mL. In this experiment, 1 ng/mL of insulin together with a Cordyceps militaris fraction was added to the 3T3-L1 adipocytes which were then incubated for 1.5 hours. And then, the glucose uptake level into the cells was compared to that in 1 ng/mL of insulin addition. All the experiments were repeated three times. In order to eliminate the case in which an isolated substance acts as a detergent regardless of the action of insulin to destroy the cell membrane so as to increase glucose uptake, the glucose uptake of the isolated substance was measured together with a substance isolated at an insulin level of 0 ng/mL, and when the measured value was higher than the basal value, it was considered not to act as an insulin-sensitive component, even it increased glucose uptake.
4-1-3. Examination of expression of protein involved in insulin signaling system For this experiment, 3T3-L1 adipocytes were treated with 2.5% trypsine and transferred into a 24-well plate. 24 hours before the experiment, the cells were starved by replacing the medium with a low-glucose Dulbecco's Modified Eagle's medium (DMEM) containing 10% fetal bovine serum. Then, the cells were washed with PBS and incubated with HEPES containing the Ceriporia lacerata culture extract and 1 ng/mL of insulin at 37 C
, for 1 hour. Then, the cells were detached from the well plate on ice using an RIPA buffer containing 50 unit aprotinin, 1 mM Na3VO4, and 1 mM PMSF. The detached cells were centrifuged at 10,000 rpm for 20 minutes at 4 C. After centrifugation, the lower layer solution was diluted with an Laemmli sample buffer, electrophoresed by SDS-PAGE and then transferred to a nitrocellulose membrane. The membrane was analyzed by Western blot using rabbit GLUT4 antibody (Chemicon, Temecula, CA), lit, P13-Kinase, Akt, MAPK, AMPK antibody, and then the optical density was determined by a laser densitometer.
4-2. Experimental results o 4-2-1. Insulin sensitivity Insulin is a therapeutic agent which is most frequently used for treatment of Type 1 diabetes and Type 2 diabetes. Insulin is a factor that promotes adipocyte differentiation, and large amounts of adipocytes are produced by action of insulin. It was shown that the EPS of the Ceriporia lacerata culture extract promoted adipocyte differentiation in a concentration-dependent manner. It was found that the EPS is a natural material that can substitute for insulin.
4-2-2. Glucose uptake 3T3-L1 fibroblasts that are preadipocytes have well established biological properties and differentiate into adipocytes when they are cultured under suitable conditions. Thus, these cells are used in studies on lipolysis inhibition or lipogenesis in the metabolic process of adipocytes. In this experiment, based on the fact that inducers such as insulin rapidly increase enzyme activity to promote differentiation, whether an insulin-sensitive component is present was examined. Specifically, 3T3-L1 adipocytes converted from 3T3-L1 fibroblasts by adding differentiation inducers such as insulin, IBMX and dexamethasone thereto were used in the experiment. Glucose uptake into the cells was determined by measuring the amount of the glucose analogue, 2-deoxy-D-[31-1]-glucose, transferred into the cells by the glucose transporter GLUT4. For the glucose uptake test, 3T3-L1 adipocytes , were starved with low-glucose DMEM 24 hours before the experiment and treated with HEPES and EPS. As a result, the glucose uptake into the cells by EPS could be seen. It was found that EPS acts as an insulin-sensitive component to increase glucose uptake in a concentration-dependent manner, and this increase in glucose uptake was higher than the control basal value.
4-2-3. Expression of protein involved on insulin signal transduction The intracellular signal transduction of insulin is involved in various complex processes. In the mechanism in which insulin acts on target cells, insulin shows various 1() actions by binding to insulin receptor in the plasma membrane.
Specifically, the insulin receptor is composed of an a-subunit and a 13-subunit, and the action of insulin begins when insulin in blood binds to the a-subunit of the insulin receptor of target cells. The activated a-subunit activates tyrosine kinase of the [3-subunit in the cell membrane. It is generally thought that the tyrosine kinase activity of the [3-subunit is the initial stage of insulin action, which is necessary for many physiological actions of insulin.
When the tyrosine kinase of the 13-subunit is activated, it phosphorylates IRS-1, IRS-2, IRS-3, IRS-4, Shc, p60 and the like which are proteins involved in the insulin signaling process, and then insulin signal transduction occurs through several down-signaling pathways with complex interactions. Among them, the tyrosine phosphorylation of IRS
results in the activation of phosphatidylinositol 3-kinase (P13-Kinase).
P13-kinase is a heterodimer composed of a 11 0-kDa catalytic subunit and an 85-kDa regulatory subunit. IRS-1 and 1RS-2 bind to p85 subunits of P13-Kinase, and then activate p110 subunits to convert phosphatidylinositide-4,5-biphosphate to phosphatidylinositide-3,4,5-triphosphate. These phosphoinositides are thought to be signaling substances that play important roles in the biological action of various growth-stimulating factors, the exact function of each of the phosphoinositides in hormone signaling processes is not yet known.
Through this P13-Kinase pathway, p70 S6 kinase downstream thereof is activated, and kinases and various proteins undergo phosphorylation and dephosphorylation signaling -processes. The activation of P13-Kinase is important in many actions following insulin stimulation, including glucose movement, lipolysis inhibition, glycogen synthesis, protein synthesis and mitogenesis, but the relationship of P13-Kinase with the occurrence of these responses is yet unclear.
Meanwhile, it is not thought that tyrosine kinase activation and tyrosine phosphorylation are always necessary for the action of insulin in all cells in all cases. It is known that there are signaling processes occurring regardless of tyrosine phosphorylation, and one of these signaling processes is a G protein signaling process. Among various G
proteins, the GTP-binding protein Ras that induces various biological signals has been most to actively studied. Ras is regulated by SOS and GTPase activating protein (GAP), and the activation of Ras sequentially induces the activation of MAP kinase kinase (MAPKK), Raf-1 MAPK/E kinase (MAPKK or MEK), p90 ribosomal S6 kinase and the like. Also, among G
proteins, ARF and Rho proteins appear to play an important role in the recirculation of a glucose carrier by activating phospholipase D, and Rab 4 protein is thought to play an important role in pathways related to the secretion of GLUT4. Some of such signaling pathways act independently or together to induce the expression of biological effects of insulin, including glucose transfer, enzyme activation, and synthesis of protein and nucleic acid. Insulin signaling processes include many signaling mechanisms and many protein substrates, and among them, IRS-1 plays a pivotal role in transferring the signal of insulin receptor to signaling substances such as P13-kinase, GRB-2, SOS, Ras, Rab 4, ARF, SYP, Nck and the like. In this experiment, the effects of the extract from the mycelial culture medium of Ceriporia laeerata that increases the expression of the glucose transporter GLUT4 on the insulin signal transduction were examined. Specifically, the intracellular level of IRS-1 that plays a pivotal role in insulin signal transduction was examined in the presence of the extract from the mycelial culture medium of Ceriporia lacerata, and the intracellular level of PI3-kinase that binds to IRS-1 to transfer the signal of insulin into cells was also examined. In addition, the intracellular level of GLUT4 that receives the signals of IRS-I and P13-Kinase to transfer glucose was also examined. As a result, it was found that . , all the proteins were phosphorylated by insulin and the expression levels thereof were increased by treatment with EPS. This suggests that EPS can promote glucose uptake through the 1R, PI3K and Alct pathways and increase the expression of AMPK
protein to promote glucose uptake, thereby improving insulin resistance.
5. Analysis of marker substance and anti-diabetic functional substance 5-1. Experimental method 100 g of CLD was suspended in 1.5 L of water, and 1.5 L of hexane was added thereto. The suspension was placed in a separatory funnel and fractionated into a hexane-insoluble layer and a hexane-soluble layer, and the upper layer was collected.
Fractionation and drying was repeated twice in the same manner as above using the same volume of hexane as the lower layer until the color of the solution became light so that the hexane-soluble substance was obtained in the largest possible amount. Subsequently, fractionation and drying was carried out in the same manner as above except for using methylene chloride, ethyl acetate and butanol. As a result, 15 g of a hexane-soluble extract, 25 g of a methylene chloride-soluble extract, 30 g of an ethyl acetate-soluble extract and 15 g of a butanol-soluble extract were obtained.
30 g of the ethyl acetate-soluble extract was subjected to silica gel column chromatography (12x60 cm, ASTM7734, Merck, Germany) using an eluent (hexane:
ethyl acetate: methanol =10:3:1), and then fractionated by TLC, thereby obtaining 15 fractions.
5-2. Separation of 2,5-dihydroxybenzoic acid Among the fractions, the 6th fraction was separated by silica gel column chromatography (1.5x12 cm, ASTM7734) using an eluent (toluene: ethyl acetate:
acetic acid=5:3:1), and then purified by TLC (developing solvent/toluene: ethyl acetate: acetic acid =5:4:1), thereby obtaining 7 mg of a compound having an Rf of 0.58. The compound was analyzed by EI-MASS and 11-I-NMR, and as a result, the compound was identified to be 2,5-dihydroxybenzoic acid having the following formula:
. , COOH
OH
HO
5-3. Separation of protocatechualdehyde Among the above fractions, the 7th fraction was separated by silica gel column chromatography (1.5x15 cm, ASTM7734) using an eluent (toluene: ethyl acetate:
acetic acid =2.5:1:0.5), and then purified by TLC (developing solvent/toluene: ethyl acetate: acetic acid =5:4:1), thereby obtaining 2 g of a compound having an Rf of 0.52. The compound was identified to be protocatechualdehyde having the following formula by EI-MASS
and 1H-NMR analysis:
CHO
OH
OH
In order to measure the contents of the above two glucose tolerance compounds, LC/MS/MS analysis was performed using Agilent 6410 (Agilent Technologies) and a negative ion source at a fi-agmentor of 150 under the following conditions:
gas temperature:
320 C; gas flow rate: 35 mL/min; and capillary volt: 4000. The HPLC column used was Epic C18, and the temperature of the column was maintained at 40 C. The mobile phase used was composed of 0.1% formic acid-containing distilled water and 0.1%
formic acid-containing acetonitrile.
-As a result, 2,5-dihydroxybenzoic acid and protocatechualdehyde, known to have anti-diabetic effects, were detected in trace amounts. The results of the analysis are shown in Table 5 below.
Table 5 Sample Protocatechualdehyde 2,5-dihydroxybenzoic acid Example 5 18.79 0.87 (pg /g) 37.65 1.32 (ttg /g) 5-3. Separation of Exopolysaccharide In order to measure the content of exopolysaccharide having excellent blood glucose lowering effects, 5 g of the extract from the mycelial culture medium of Ceriporia lacerata was sufficiently suspended in 100 mL of distilled water, and the suspension was centrifuged at 8,000 rpm for 20 minutes. A 2-3-fold amount of cold alcohol was added to the supernatant which was then placed in a refrigerator at 4 C and allowed to stand for 12 hours.
The supernatant in the solution which had been allowed to stand was centrifuged again at 8,000 rpm for 20 minutes, and the precipitate was collected, thereby extracting crude exopolysaccharide. The crude exopolysaccharide was freeze-dried, and as a result, it was shown to have an exopolysaccharide content of 5.5 0.5%/100 mg. The sugar and protein contents of the EPS were measured, and as a result, it was shown that the sugar content was about 40% and the protein content was about 33%, suggesting that the EPS is a polysaccharide composed of sugar bonded with protein.
As described above, according to the present invention, there can be provided an extract from the mycelial culture medium of Ceriporia lacerata containing 5.5 0.5%/100 mg of exopolysaccharide having excellent blood glucose lowering effects, 18.790.87 itg/g of protocatechualdehyde and 37.65 1.32 i.tg/g of 2,5-dihydroxybenzoic acid.
6. Toxicity and efficacy tests in rodents Tests for the safety and efficacy of the extract from the mycelial culture medium of Ceriporia lacerata were performed by K company (received a GLP certificate) in accordance with Good Laboratory Practice (GLP). As a result, it was found that the extract from the mycelial culture medium of Ceriporia lacerata exhibited statistically significant increase of pancreatic beta-cells in Type 2 diabetes rats (increased the weight of pancreas, spleen and thymus) and was safer and more effective than Metformin (Pfizer) which was used as a positive control drug (Table 6).
Table 6 General toxicity A single dose toxicity test on rodents 7 weeks Toxicity test on rodents for 4 weeks repeated oral administration-DRF 8 weeks Toxicity test on rodents for 13 weeks repeated oral administration 27 weeks (including recovered group) A single dose toxicity test on non-rodents 8 weeks Result Nontoxic reaction Heredity toxicity test Back mutation test (including preliminary test) 4 weeks Chromosomal anomaly test (including preliminary test) 8 weeks Micro nucleus test (including preliminary test) 8 weeks Result Negative re:action Effect test Oral glucose tolerance test 4 weeks Effect test on blood sugar dropping after being caused Type I diabetes by STZ
8 weeks Curing diabetes using db/db mice 8 weeks Result B-cell in pancreas with Type 2 diabetes rats increased meaningfully in statistics, and it is judged that it is a fundamental diabetes medicine being recorded with safe and excellent effect compared to Metformin by Pfizer used as a comparison medicine.
INDUSTRIAL APPLICABILITY
The present invention relates to a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata and a pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications prepared by the preparation method, which has high industrial applicability.
3-1-4. Oral glucose tolerance test (OGTT) The animals were fasted for 12 hours or more, and the fasting blood glucose level was measured. Each of samples obtained by dissolving each of the Ceriporia lacerata powder and EPS in distilled water at various concentrations was administered orally to five animals of each group. The control group was administered with the same amount of saline.
Next, the groups other than the control group were orally administered with 40% glucose at a dose of 2 g/kg bw, and blood was collected from the tail vein at 30, 60, 90 and 120 minutes after glucose administration to observe a change in the blood glucose level.
The increase in the blood glucose level at each point of time was calculated to plot a blood glucose curve.
3-1-5. Sacrifice of experimental animals and sampling Blood glucose levels should be measured in tail veins after 12-hr fasting, and blood for biochemical analysis should be collected after fasting of 12 hours or more. Thus, the sacrifice of the experimental animals was performed 2 days after 6th blood glucose level measurement at 6 weeks after the start of rearing.
For sacrifice of the experimental animals, all the animals were fasted for 12 hours and anesthetized with ether. Blood was taken from the saphenous vein and placed in a tube for serum separation. Then, the blood was centrifuged at 3,000 rpm for 20 minutes to obtain serum which was to be used as a sample for analysis of biochemical markers.
Immediately after sacrifice, the liver, abdominal fat and the like were extracted from all the to animals, weighed, fast-frozen at -80 C and stored until use. Portions of the extracted liver and pancreas were fixed in 4% paraformaldehyde solution and subjected to histological analysis.
3-1-6. Serum c-peptide, insulin and leptin levels The serum c-peptide, insulin and leptin levels that are blood glucose-related functional indices were measured from the serum (collected from the saphenous vein) using double antibody C-peptide (DPC, USA), an insulin RIA kit (DPC, USA), and a mouse leptin RLA kit (L1NCO, USA), respectively, by a radioimmunoassay.
3-2. Experimental results 3-2-1. Changes in food intake and weight FIGs. 14, 15 and 16 show the changes in weight, food intake and water intake of the experimental animals for 6 weeks. The initial bodyweights of the diabetes control group and the EPS-administered group were similar (about 32 g). Also, there was no significant difference in bodyweight after 6 weeks between the diabetes control group and the test groups, and the bodyweig,ht showed a tendency to increase throughout the experimental period. The feed and water intakes were higher in the diabetes control group than in the . .
normal control group, and the water and feed intakes of the positive control group MET300 were significantly lower than those of other groups.
3-2-2. Organ weight The weights of liver, kidney, spleen, kidney fat and abdominal fat of the experimental animals were measured, and the results of the measurement are shown in Table 4 below.
Table 4 Liver Kidney Spleen Kidney fat Abdominal fat (W/BW) (W/BW) (W/BW) (W/BW) (W/BW) NC 0.94 0.14 0.29 0.03 0.06 0.01 0.12 0.04 0.43 0.17 DM 2.89 0.04 0.41 0.06 0.04 0.02 0.82 0.17 2.34 0.28 DM-EX0150 2.50 0.29 0.39 + 0.05 0.06 0.03 0.63 0.12 2.48 0.14 DM-EX0300 2.65 0.05 0.40 0.04 0.05 + 0.02 0.55 0.17 2.55 0.15 DM-MET300 2.60 + 0.19 0.39 0.03 0.03 0.02 0.89 0.13 2.564 0.33 DM-ALL300 2.50 0.27 0.40 + 0.03 0.06 0.01 0.48 + 0.12 2.41 + 0.21 The liver weight showed a tendency to increase rapidly in the diabetes-induced group and showed a tendency to significantly decrease in the groups administered with the sample. These results are consistent with the report that fat is accumulated in the liver upon the induction of diabetes to increase the liver volume. With respect to the kidney, it is known that the kidney volume increases with an increase in glomerular filtration rate in the initial stage of development of diabetes. In this study, the weight of the kidney also showed a tendency to increase, but this increase was not significant. In addition, the weight of the spleen did not significantly differ among the groups. The weight of the kidney fat increased rapidly in the diabetes-induced group, but was significantly decreased by administration of =
EPS and Ceriporia lacerata powder. In addition, the weight of the abdominal fat did not significantly differ among the groups.
3-2-3. Effect on change in blood glucose level FIG. 16 shows the results of measuring the change in blood glucose levels after 12-hr fasting. The initial blood glucose level was similar (about 150 mg/dL) -among the groups, but started to increase slightly from one week after administration of the sample. After 3 weeks, the blood glucose level increased rapidly so that the diabetes control group showed a blood glucose level of about 400 mg/dL, whereas the metformin group showed no increase in to the blood glucose level. After that, the blood glucose level continued to increase, but the groups administered with EPS and Ceriporia lacerata powder showed a significant decrease in the blood glucose level compared to the diabetes control group.
3-2-4. Oral glucose tolerance The oral glucose tolerance of EPS and Ceriporia lacerata powder was measured at 6 week of sample administration, and the results of the measurement are shown in FIG. 17.
The diabetes control group showed a blood glucose level of 600 mg/dL which is the highest value measurable by the blood glucose meter, and it maintained high blood glucose levels throughout the glucose tolerance test. On the other hand, the group administered with EPS
and Ceriporia lacerata powder showed an initial fasting blood glucose level of 500 mg/dL
which was significantly lower than that of the diabetes control group.
However, the blood glucose level of the group administered with EPS and Ceriporia lacerata powder increased gradually with the passage of time and was 600 mg/dL (the highest value measurable by the blood glucose meter) after 30 minutes. Thereafter, the blood glucose level gradually decreased, and after 180 minutes, the blood glucose level was restored to 520 mg/dL which was similar to the initial blood glucose level.
3-2-5. Blood glucose level The blood glucose levels of the animals sacrificed after 6-week oral administration of EPS were measured. As a result, it was shown that the blood glucose level of the DM group increased to about 900 mg/dL, whereas the blood glucose levels of the groups administered with the sample decreased in a manner dependent on the concentration of the sample.
Specifically, the blood glucose level of the EPS 300 group decreased to about 700 mg/dL, suggesting that EPS plays a positive role in lowering blood glucose levels.
3-2-6. Effect on serum lipid levels The serum lipid levels of the animals sacrificed after 6-week oral administration of EPS were measured. As a result, it was shown that the total cholesterol and triglyceride levels were about two times higher in the DM group than in the NC group, but were significantly lowered in the group administered with EPS. In addition, the group administered with EPS showed a significant increase in the HDL cholesterol and a significant decrease in the LDL-cholesterol level, indicating that EPS is a substance that reduces serum lipid levels in Type 2 diabetes models without changing the bodyweight.
3-2-7. Effects on insulin, C-peptide and leptin levels The serum insulin, C-peptide and leptin levels of the animals sacrificed after 6-week oral administration of EPS were measured. As a result, it was shown that the insulin level did not significantly differ among the groups, and the C-peptide level was higher in the sample-administered groups than in the DM group, suggesting that EPS activates insulin secretion in the pancreas. In addition, the leptin level also increased in the sample-administered groups, suggesting that EPS plays a positive role in insulin resistance.
4. Effect of exopolysaccharide on insulin signal transduction in 3T3-L1 cells 4-1. Experimental method 4-1-1. Cell culture , 3T3-L1 fibroblasts that are preadipocytes have well established biological properties and differentiate into adipocytes when they are cultured under suitable conditions. These cells are used in studies on lipolysis inhibition or lipogenesis in the metabolic process of adipocytes. In addition, adipocytes that are insulin target cells are frequently used in studies on insulin signal transduction. The 3T3-L1 fibroblasts used in the experiment were obtained from the Korean Cell Line Bank and were cultured in Dulbecco's Modified Eagle's Medium (DMEM, GibcoBRL) (containing 10% fetal bovine serum (FBS, GibcoBRL), mM glutaMAX (GibcoBRL), penicillin (10,000 units/mL, Sigma), streptomycin (10 mg/mL, Sigma) under the conditions of 37 C and 10% CO2 while the medium was replaced with high-glucose medium at 3-day intervals. When the 3T3-L1 fibroblasts reached a confluence of 60-80%, the cultured cells were washed with Dulbecco's phosphate buffered saline (PBS, GibcoBRL). These cells were subcultured in a 75 cm2 flask containing 500 lit of 2.5%
trypsin (GibcoBRL) at 37 C for 5 minutes, after which the cells were detached from the flask.
The detached cells were transferred into a fresh flask containing 15 mL of a high-glucose DMEM medium supplemented with 10% FBS.
4-1-2. Glucose uptake into adipocytes 3T3-L1 fibroblasts were cultured to confluence in the same manner as the above cell culture. 2 days after confluence, the cells were cultured for 3 days in a high-glucose DMEM medium containing 0.5 mM 3-isobuty1-1-methyl-xanthine (1BMX, Sigma), 25 jM
dexamethasone (DEX, Sigma) and insulin (Sigma) which are differentiation inducers, and the medium was replaced with a fresh medium at 2-day intervals, whereby the cells were converted to adipocytes. Between 10 days and 15 days during which the preadipocytes were completely converted to adipocytes, a glucose uptake test was performed.
In the glucose uptake test that reflects insulin sensitivity, the 3T3-L1 cells that had been completely converted to adipocytes were treated with 2.5% typsine, and then seeded into a 24-well plate at a concentration of 20x 104 cells/mL as counted by a hemacytometer. The medium was replaced with a low-glucose DMEM medium to starve the cells. The adipocytes in the well plate were washed with PBS and then incubated with a HEPES solution containing 0.1%
bovine serum albumin (BSA, Roche), each of 1 pg/mL and 10 Rg/mL of the Ceriporia lacerata culture extract and insulin at 37 C for 1.5 hours. Then, 10 Ci/mL of the glucose analogue, 2-deoxy-D-[31-1] glucose (2-DG), was added to the cells which were then incubated at 37 C for 10 minutes. After 10 minutes, the cells were washed five times with PBS, lysed with 1N NaOH and neutralized with 1N HC1. The amount of 3H uptake into the cells was measured with a beta-counter (Tri-Carb 21001R, Packard Bioscince, FL) for 5 minutes. In order to eliminate non-specific glucose uptake, cells incubated with cytochalasin B (Sigma) that inhibits the activity of glucose transporter 4 (GLUT4) was also measured.
In the process of examining whether an insulin-sensitive component is contained in the Ceriporia lacerata culture, low-concentration insulin was chosen to be 1 ng/mL and high-concentration insulin was chosen to be 25 ng/mL, because insulin uptake into the cells was the highest at an insulin concentration of 50 ng/mL. In this experiment, 1 ng/mL of insulin together with a Cordyceps militaris fraction was added to the 3T3-L1 adipocytes which were then incubated for 1.5 hours. And then, the glucose uptake level into the cells was compared to that in 1 ng/mL of insulin addition. All the experiments were repeated three times. In order to eliminate the case in which an isolated substance acts as a detergent regardless of the action of insulin to destroy the cell membrane so as to increase glucose uptake, the glucose uptake of the isolated substance was measured together with a substance isolated at an insulin level of 0 ng/mL, and when the measured value was higher than the basal value, it was considered not to act as an insulin-sensitive component, even it increased glucose uptake.
4-1-3. Examination of expression of protein involved in insulin signaling system For this experiment, 3T3-L1 adipocytes were treated with 2.5% trypsine and transferred into a 24-well plate. 24 hours before the experiment, the cells were starved by replacing the medium with a low-glucose Dulbecco's Modified Eagle's medium (DMEM) containing 10% fetal bovine serum. Then, the cells were washed with PBS and incubated with HEPES containing the Ceriporia lacerata culture extract and 1 ng/mL of insulin at 37 C
, for 1 hour. Then, the cells were detached from the well plate on ice using an RIPA buffer containing 50 unit aprotinin, 1 mM Na3VO4, and 1 mM PMSF. The detached cells were centrifuged at 10,000 rpm for 20 minutes at 4 C. After centrifugation, the lower layer solution was diluted with an Laemmli sample buffer, electrophoresed by SDS-PAGE and then transferred to a nitrocellulose membrane. The membrane was analyzed by Western blot using rabbit GLUT4 antibody (Chemicon, Temecula, CA), lit, P13-Kinase, Akt, MAPK, AMPK antibody, and then the optical density was determined by a laser densitometer.
4-2. Experimental results o 4-2-1. Insulin sensitivity Insulin is a therapeutic agent which is most frequently used for treatment of Type 1 diabetes and Type 2 diabetes. Insulin is a factor that promotes adipocyte differentiation, and large amounts of adipocytes are produced by action of insulin. It was shown that the EPS of the Ceriporia lacerata culture extract promoted adipocyte differentiation in a concentration-dependent manner. It was found that the EPS is a natural material that can substitute for insulin.
4-2-2. Glucose uptake 3T3-L1 fibroblasts that are preadipocytes have well established biological properties and differentiate into adipocytes when they are cultured under suitable conditions. Thus, these cells are used in studies on lipolysis inhibition or lipogenesis in the metabolic process of adipocytes. In this experiment, based on the fact that inducers such as insulin rapidly increase enzyme activity to promote differentiation, whether an insulin-sensitive component is present was examined. Specifically, 3T3-L1 adipocytes converted from 3T3-L1 fibroblasts by adding differentiation inducers such as insulin, IBMX and dexamethasone thereto were used in the experiment. Glucose uptake into the cells was determined by measuring the amount of the glucose analogue, 2-deoxy-D-[31-1]-glucose, transferred into the cells by the glucose transporter GLUT4. For the glucose uptake test, 3T3-L1 adipocytes , were starved with low-glucose DMEM 24 hours before the experiment and treated with HEPES and EPS. As a result, the glucose uptake into the cells by EPS could be seen. It was found that EPS acts as an insulin-sensitive component to increase glucose uptake in a concentration-dependent manner, and this increase in glucose uptake was higher than the control basal value.
4-2-3. Expression of protein involved on insulin signal transduction The intracellular signal transduction of insulin is involved in various complex processes. In the mechanism in which insulin acts on target cells, insulin shows various 1() actions by binding to insulin receptor in the plasma membrane.
Specifically, the insulin receptor is composed of an a-subunit and a 13-subunit, and the action of insulin begins when insulin in blood binds to the a-subunit of the insulin receptor of target cells. The activated a-subunit activates tyrosine kinase of the [3-subunit in the cell membrane. It is generally thought that the tyrosine kinase activity of the [3-subunit is the initial stage of insulin action, which is necessary for many physiological actions of insulin.
When the tyrosine kinase of the 13-subunit is activated, it phosphorylates IRS-1, IRS-2, IRS-3, IRS-4, Shc, p60 and the like which are proteins involved in the insulin signaling process, and then insulin signal transduction occurs through several down-signaling pathways with complex interactions. Among them, the tyrosine phosphorylation of IRS
results in the activation of phosphatidylinositol 3-kinase (P13-Kinase).
P13-kinase is a heterodimer composed of a 11 0-kDa catalytic subunit and an 85-kDa regulatory subunit. IRS-1 and 1RS-2 bind to p85 subunits of P13-Kinase, and then activate p110 subunits to convert phosphatidylinositide-4,5-biphosphate to phosphatidylinositide-3,4,5-triphosphate. These phosphoinositides are thought to be signaling substances that play important roles in the biological action of various growth-stimulating factors, the exact function of each of the phosphoinositides in hormone signaling processes is not yet known.
Through this P13-Kinase pathway, p70 S6 kinase downstream thereof is activated, and kinases and various proteins undergo phosphorylation and dephosphorylation signaling -processes. The activation of P13-Kinase is important in many actions following insulin stimulation, including glucose movement, lipolysis inhibition, glycogen synthesis, protein synthesis and mitogenesis, but the relationship of P13-Kinase with the occurrence of these responses is yet unclear.
Meanwhile, it is not thought that tyrosine kinase activation and tyrosine phosphorylation are always necessary for the action of insulin in all cells in all cases. It is known that there are signaling processes occurring regardless of tyrosine phosphorylation, and one of these signaling processes is a G protein signaling process. Among various G
proteins, the GTP-binding protein Ras that induces various biological signals has been most to actively studied. Ras is regulated by SOS and GTPase activating protein (GAP), and the activation of Ras sequentially induces the activation of MAP kinase kinase (MAPKK), Raf-1 MAPK/E kinase (MAPKK or MEK), p90 ribosomal S6 kinase and the like. Also, among G
proteins, ARF and Rho proteins appear to play an important role in the recirculation of a glucose carrier by activating phospholipase D, and Rab 4 protein is thought to play an important role in pathways related to the secretion of GLUT4. Some of such signaling pathways act independently or together to induce the expression of biological effects of insulin, including glucose transfer, enzyme activation, and synthesis of protein and nucleic acid. Insulin signaling processes include many signaling mechanisms and many protein substrates, and among them, IRS-1 plays a pivotal role in transferring the signal of insulin receptor to signaling substances such as P13-kinase, GRB-2, SOS, Ras, Rab 4, ARF, SYP, Nck and the like. In this experiment, the effects of the extract from the mycelial culture medium of Ceriporia laeerata that increases the expression of the glucose transporter GLUT4 on the insulin signal transduction were examined. Specifically, the intracellular level of IRS-1 that plays a pivotal role in insulin signal transduction was examined in the presence of the extract from the mycelial culture medium of Ceriporia lacerata, and the intracellular level of PI3-kinase that binds to IRS-1 to transfer the signal of insulin into cells was also examined. In addition, the intracellular level of GLUT4 that receives the signals of IRS-I and P13-Kinase to transfer glucose was also examined. As a result, it was found that . , all the proteins were phosphorylated by insulin and the expression levels thereof were increased by treatment with EPS. This suggests that EPS can promote glucose uptake through the 1R, PI3K and Alct pathways and increase the expression of AMPK
protein to promote glucose uptake, thereby improving insulin resistance.
5. Analysis of marker substance and anti-diabetic functional substance 5-1. Experimental method 100 g of CLD was suspended in 1.5 L of water, and 1.5 L of hexane was added thereto. The suspension was placed in a separatory funnel and fractionated into a hexane-insoluble layer and a hexane-soluble layer, and the upper layer was collected.
Fractionation and drying was repeated twice in the same manner as above using the same volume of hexane as the lower layer until the color of the solution became light so that the hexane-soluble substance was obtained in the largest possible amount. Subsequently, fractionation and drying was carried out in the same manner as above except for using methylene chloride, ethyl acetate and butanol. As a result, 15 g of a hexane-soluble extract, 25 g of a methylene chloride-soluble extract, 30 g of an ethyl acetate-soluble extract and 15 g of a butanol-soluble extract were obtained.
30 g of the ethyl acetate-soluble extract was subjected to silica gel column chromatography (12x60 cm, ASTM7734, Merck, Germany) using an eluent (hexane:
ethyl acetate: methanol =10:3:1), and then fractionated by TLC, thereby obtaining 15 fractions.
5-2. Separation of 2,5-dihydroxybenzoic acid Among the fractions, the 6th fraction was separated by silica gel column chromatography (1.5x12 cm, ASTM7734) using an eluent (toluene: ethyl acetate:
acetic acid=5:3:1), and then purified by TLC (developing solvent/toluene: ethyl acetate: acetic acid =5:4:1), thereby obtaining 7 mg of a compound having an Rf of 0.58. The compound was analyzed by EI-MASS and 11-I-NMR, and as a result, the compound was identified to be 2,5-dihydroxybenzoic acid having the following formula:
. , COOH
OH
HO
5-3. Separation of protocatechualdehyde Among the above fractions, the 7th fraction was separated by silica gel column chromatography (1.5x15 cm, ASTM7734) using an eluent (toluene: ethyl acetate:
acetic acid =2.5:1:0.5), and then purified by TLC (developing solvent/toluene: ethyl acetate: acetic acid =5:4:1), thereby obtaining 2 g of a compound having an Rf of 0.52. The compound was identified to be protocatechualdehyde having the following formula by EI-MASS
and 1H-NMR analysis:
CHO
OH
OH
In order to measure the contents of the above two glucose tolerance compounds, LC/MS/MS analysis was performed using Agilent 6410 (Agilent Technologies) and a negative ion source at a fi-agmentor of 150 under the following conditions:
gas temperature:
320 C; gas flow rate: 35 mL/min; and capillary volt: 4000. The HPLC column used was Epic C18, and the temperature of the column was maintained at 40 C. The mobile phase used was composed of 0.1% formic acid-containing distilled water and 0.1%
formic acid-containing acetonitrile.
-As a result, 2,5-dihydroxybenzoic acid and protocatechualdehyde, known to have anti-diabetic effects, were detected in trace amounts. The results of the analysis are shown in Table 5 below.
Table 5 Sample Protocatechualdehyde 2,5-dihydroxybenzoic acid Example 5 18.79 0.87 (pg /g) 37.65 1.32 (ttg /g) 5-3. Separation of Exopolysaccharide In order to measure the content of exopolysaccharide having excellent blood glucose lowering effects, 5 g of the extract from the mycelial culture medium of Ceriporia lacerata was sufficiently suspended in 100 mL of distilled water, and the suspension was centrifuged at 8,000 rpm for 20 minutes. A 2-3-fold amount of cold alcohol was added to the supernatant which was then placed in a refrigerator at 4 C and allowed to stand for 12 hours.
The supernatant in the solution which had been allowed to stand was centrifuged again at 8,000 rpm for 20 minutes, and the precipitate was collected, thereby extracting crude exopolysaccharide. The crude exopolysaccharide was freeze-dried, and as a result, it was shown to have an exopolysaccharide content of 5.5 0.5%/100 mg. The sugar and protein contents of the EPS were measured, and as a result, it was shown that the sugar content was about 40% and the protein content was about 33%, suggesting that the EPS is a polysaccharide composed of sugar bonded with protein.
As described above, according to the present invention, there can be provided an extract from the mycelial culture medium of Ceriporia lacerata containing 5.5 0.5%/100 mg of exopolysaccharide having excellent blood glucose lowering effects, 18.790.87 itg/g of protocatechualdehyde and 37.65 1.32 i.tg/g of 2,5-dihydroxybenzoic acid.
6. Toxicity and efficacy tests in rodents Tests for the safety and efficacy of the extract from the mycelial culture medium of Ceriporia lacerata were performed by K company (received a GLP certificate) in accordance with Good Laboratory Practice (GLP). As a result, it was found that the extract from the mycelial culture medium of Ceriporia lacerata exhibited statistically significant increase of pancreatic beta-cells in Type 2 diabetes rats (increased the weight of pancreas, spleen and thymus) and was safer and more effective than Metformin (Pfizer) which was used as a positive control drug (Table 6).
Table 6 General toxicity A single dose toxicity test on rodents 7 weeks Toxicity test on rodents for 4 weeks repeated oral administration-DRF 8 weeks Toxicity test on rodents for 13 weeks repeated oral administration 27 weeks (including recovered group) A single dose toxicity test on non-rodents 8 weeks Result Nontoxic reaction Heredity toxicity test Back mutation test (including preliminary test) 4 weeks Chromosomal anomaly test (including preliminary test) 8 weeks Micro nucleus test (including preliminary test) 8 weeks Result Negative re:action Effect test Oral glucose tolerance test 4 weeks Effect test on blood sugar dropping after being caused Type I diabetes by STZ
8 weeks Curing diabetes using db/db mice 8 weeks Result B-cell in pancreas with Type 2 diabetes rats increased meaningfully in statistics, and it is judged that it is a fundamental diabetes medicine being recorded with safe and excellent effect compared to Metformin by Pfizer used as a comparison medicine.
INDUSTRIAL APPLICABILITY
The present invention relates to a method for preparing an extract from the mycelial culture medium of Ceriporia lacerata and a pharmaceutical composition for preventing or treating diabetic diseases and diabetic complications prepared by the preparation method, which has high industrial applicability.
Claims (13)
1. A purified exopolysaccharide (EPS) having a molecular weight of about 120 kDa for use in the prevention or treatment of a diabetic disease or a diabetic complication, wherein said exopolysaccharide is obtained from a culture medium of Ceriporia lacerate mycelia.
2. The purified exopolysaccharide of claim 1, wherein the diabetic disease is Type 2 diabetes.
3. The purified exopolysaccharide of claim 1 or 2, for use in the treatment of the diabetic disease.
4. The purified exopolysaccharide of claim 1, wherein the diabetic complication is hyperglycemia, atherosclerosis, microangiopathy, diabetic retinopathy or kidney disease.
5. The purified exopolysaccharide of claim 1 or 4, for use in the treatment of the diabetic complication.
6. The purified exopolysaccharide of any one of claims 1-5, wherein the exopolysaccharide is comprised of about 40 weight% of sugar and about 33 weight% of protein.
7. Use of a purified exopolysaccharide (EPS) having a molecular weight of about 120 kDa for the prevention or treatment of a diabetic disease or a diabetic complication, wherein said exopolysaccharide is obtained from a culture medium of Ceriporia lacerate mycelia.
8. Use of a purified exopolysaccharide (EPS) having a molecular weight of about 120 kDa in the preparation of a medicament for the prevention or treatment of a diabetic disease or a diabetic complication, wherein said exopolysaccharide is obtained from a culture medium of Ceriporia lacerate mycelia.
9. The use of claim 7 or 8, wherein the diabetic disease is Type 2 diabetes.
10. The use of any one of claims 7-9, for the treatment of the diabetic disease.
11. The use of claim 7 or 8, wherein the diabetic complication is hyperglycemia, atherosclerosis, microangiopathy, diabetic retinopathy or kidney disease.
12. The use of any one of claims 7-8 or 11, for the treatment of the diabetic complication.
13. The use of any one of claims 7-12, wherein the exopolysaccharide is comprised of about 40 weight% of sugar and about 33 weight% of protein.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2013/000398 WO2014112666A1 (en) | 2013-01-18 | 2013-01-18 | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2897955A1 CA2897955A1 (en) | 2014-07-24 |
CA2897955C true CA2897955C (en) | 2018-01-16 |
Family
ID=51209750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2897955A Active CA2897955C (en) | 2013-01-18 | 2013-01-18 | Extract from culture medium of ceriporia lacerata for prevention or treatment of diabetic diseases and complications |
Country Status (9)
Country | Link |
---|---|
JP (1) | JP2016506719A (en) |
KR (1) | KR20150103690A (en) |
CN (1) | CN105142655B (en) |
AU (1) | AU2013374516B2 (en) |
BR (1) | BR112015017069A2 (en) |
CA (1) | CA2897955C (en) |
DE (1) | DE112013006456T5 (en) |
GB (1) | GB2529557A (en) |
WO (1) | WO2014112666A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101682096B1 (en) * | 2014-11-03 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Tranquilizer composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101645652B1 (en) * | 2014-11-03 | 2016-08-08 | (주)퓨젠바이오농업회사법인 | Sexual function improvement composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101682093B1 (en) * | 2014-11-03 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Blood pressure reducing composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101737627B1 (en) * | 2014-11-27 | 2017-05-19 | (주)퓨젠바이오 | Antioxidant composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101691972B1 (en) * | 2015-01-30 | 2017-01-02 | (주)퓨젠바이오농업회사법인 | Pharmaceutical composition for the prevention or treatment of a cancer comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101712590B1 (en) * | 2015-08-06 | 2017-03-07 | (주)퓨젠바이오농업회사법인 | Composition for relieving fatigue comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101682108B1 (en) * | 2015-10-08 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101655882B1 (en) * | 2015-10-08 | 2016-09-08 | (주)퓨젠바이오농업회사법인 | Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101655878B1 (en) * | 2015-10-08 | 2016-09-08 | (주)퓨젠바이오농업회사법인 | Composition for preventing hair loss and enhancing hair growth comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR101682104B1 (en) * | 2015-11-26 | 2016-12-02 | (주)퓨젠바이오농업회사법인 | Composition for kidney protection comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
KR102150595B1 (en) * | 2017-06-30 | 2020-09-01 | (주)퓨젠바이오 | Pharmaceutical composition for treating scar comprising culture medium of ceriporia lacerata |
KR101925890B1 (en) * | 2018-08-02 | 2018-12-06 | 김병천 | Novel strain of Ceriporia lacerata-K1, and composition comprising its culture for preventing or treating diabetes mellitus |
KR101981571B1 (en) * | 2018-10-12 | 2019-05-24 | 김병천 | Composition comprising product of two stage cultivation using Ganoderma applanatum and Ceriporia lacerata K1 mycelium for preventing or treating hepatic injury |
KR101969433B1 (en) * | 2018-10-12 | 2019-04-17 | 김병천 | Composition comprising product of two stage cultivation using Ganoderma applanatum and Ceriporia lacerata K1 mycelium for preventing or treating diabetes mellitus |
CN111518825B (en) * | 2020-04-30 | 2022-10-11 | 浙江工业大学 | Method for preparing cordyceps militaris polysaccharide through polygene combined expression |
KR102297056B1 (en) * | 2020-08-20 | 2021-09-06 | 주식회사 마이셀랩 | Culture broth of Porostereum sp.(KCTC18837P) and composition comprising the same for preventing or treating diabetes mellitus |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101138464B1 (en) * | 2004-07-06 | 2012-04-25 | 환인제약 주식회사 | Inonotus obliqqus WI0628, its extract with antidiabetic activity and its extraction method |
JP2008245629A (en) * | 2007-03-30 | 2008-10-16 | Kyushu Univ | Microbial preparation for treatment of woody waste |
JP5561637B2 (en) * | 2010-02-16 | 2014-07-30 | 国立大学法人鳥取大学 | Antibacterial / sterilization technology using mushroom volatile antibacterial substances |
KR101031605B1 (en) * | 2010-11-11 | 2011-04-27 | 김병천 | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same |
CN102807956B (en) * | 2012-07-12 | 2014-04-16 | 华东理工大学 | Ceriporia lacerata strain and application thereof |
-
2013
- 2013-01-18 GB GB1514369.6A patent/GB2529557A/en not_active Withdrawn
- 2013-01-18 BR BR112015017069A patent/BR112015017069A2/en not_active IP Right Cessation
- 2013-01-18 DE DE112013006456.1T patent/DE112013006456T5/en not_active Withdrawn
- 2013-01-18 AU AU2013374516A patent/AU2013374516B2/en active Active
- 2013-01-18 CN CN201380070856.XA patent/CN105142655B/en active Active
- 2013-01-18 WO PCT/KR2013/000398 patent/WO2014112666A1/en active Application Filing
- 2013-01-18 CA CA2897955A patent/CA2897955C/en active Active
- 2013-01-18 KR KR1020157019761A patent/KR20150103690A/en not_active Application Discontinuation
- 2013-01-18 JP JP2015553637A patent/JP2016506719A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
GB201514369D0 (en) | 2015-09-30 |
KR20150103690A (en) | 2015-09-11 |
BR112015017069A2 (en) | 2017-07-11 |
WO2014112666A1 (en) | 2014-07-24 |
CN105142655A (en) | 2015-12-09 |
DE112013006456T5 (en) | 2015-10-01 |
CN105142655B (en) | 2020-11-17 |
AU2013374516B2 (en) | 2017-02-02 |
GB2529557A (en) | 2016-02-24 |
JP2016506719A (en) | 2016-03-07 |
AU2013374516A1 (en) | 2015-08-27 |
CA2897955A1 (en) | 2014-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2897955C (en) | Extract from culture medium of ceriporia lacerata for prevention or treatment of diabetic diseases and complications | |
US20140193454A1 (en) | Method from preparing ceriporia lacerata culture extract and pharmaceutical composition for prevention or treatment of diabetes and diabetic complications comprising ceriporia lacerata culture extract as active ingredient | |
Cheng et al. | Studies on anti-inflammatory activity of sulfated polysaccharides from cultivated fungi Antrodia cinnamomea | |
JP6644002B2 (en) | Algal extract for use as an immunomodulator | |
JP5658479B2 (en) | Composition showing activity such as fat reduction | |
Thakur et al. | 1-Deoxynojirimycin, its potential for management of non-communicable metabolic diseases | |
CN108403498B (en) | Preparation method and application of natto extracting solution | |
KR101356611B1 (en) | Vinegar of fermented pepper leaf with increased AGI activity and method for preparing the same | |
WO2016010182A1 (en) | Composition for improving liver function comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata | |
CN113599467A (en) | Tibetan red yeast, Tibetan medicine red yeast extract, preparation method and application | |
Jeong et al. | Polysaccharides from edible mushroom Hinmogi (Tremella fuciformis) inhibit differentiation of 3T3-L1 adipocytes by reducing mRNA expression of PPARγ, C/EBPα, and leptin | |
JP6157706B2 (en) | Preparation method of culture liquid extract of Serlipria racerata and pharmaceutical composition for prevention or treatment of diabetic diseases and diabetic complications containing culture liquid extract of serlipria racerata prepared therefrom as an active ingredient | |
CN103191106A (en) | Application of genipin amino acid derivative as NF-kappa B inhibitor | |
KR20170022562A (en) | Screening method of the effective material for treating and preventing complex metabolic disease accompanying diabetes and obesity | |
Wang et al. | Dietary supplementation with Tolypocladium sinense mycelium prevents dyslipidemia inflammation in high fat diet mice by modulation of gut microbiota in mice | |
KR100963511B1 (en) | Exopolysaccharides for type 2 diabetes therapy from Phellinus baumii mycellium and a preparation method thereof | |
CN105878234B (en) | Application of the atractylenolide Ⅰ in the drug and health care product of preparation enhancing immune function | |
Dong et al. | Active peptides from Eupolyphaga sinensis walker attenuates experimental hyperlipidemia by regulating the gut microbiota and biomarkers in rats with dyslipidemia | |
CN112716937B (en) | Active ingredient composition with synergistic blood sugar reducing function and preparation method thereof | |
Hwang et al. | Modern Biotechnology of Phellinus baumii--From Fermentation to Proteomics. | |
Yu et al. | The regulation effect of crude polysaccharides from cordyceps militaris on obesity control and gut microbiota community via high-fat diet-fed mice model | |
TWI394567B (en) | Pharmaceutical composition for activating expression of pparγ or decreasing blood glucose | |
Jing et al. | Production of Corn Protein Hydrolysate with Glutamine-Rich Peptides and Its Antagonistic Function in Ulcerative Colitis In Vivo. Foods 2022, 11, 3359 | |
CN117903243A (en) | Fructus cannabis extract polypeptide and application thereof | |
Chen et al. | Extract of white sweet potato tuber against TNF-α-induced insulin resistant by activating the PI3K/Akt pathway in C2C12 myotubes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20150710 |